Polypept(o)ides: origins, synthesis, applications and future directions

Bauer, T.A.; Simić, L.; Guyse, J.F.R. van; Duro-Castaño, A.; Nebot, V.J.; Barz, M.

# Polypept(o)ides – Origins, synthesis, applications and future directions

Tobias Alexander Bauer [a,1], Leon Simić [a,b,1], Joachim F.R. Van Guyse [a], Aroa Duro-Castaño [c], Vicent J. Nebot [c], Matthias Barz [a,b,*]

[a] Leiden Academic Center for Drug Research (LACDR), Biotherapeutics Division, Leiden University, Einsteinweg 55, Leiden 2333CC, the Netherlands
[b] Department of Dermatology, University Medical Center, Johannes Gutenberg-University Mainz (JGU), Obere Zahlbacher Straße 63, 55131 Mainz, Germany
[c] Curapath, Av. Benjamin Franklin 19, 46980 Paterna, Valencia, Spain

ARTICLE INFO

ABSTRACT

Polypept(o)ides combine the stealth-like properties of polypeptoids such as polysarcosine (poly(*N*-methyl glycine), pSar) with the multifunctionality and intrinsic stimuli-responsiveness of synthetic polypeptides. This class of copolymers can be synthesized by controlled living ring-opening polymerization of the corresponding α-amino acid *N*-carboxyanhydrides (NCAs) and *N*-substituted glycine *N*-carboxyanhydrides (NNCAs). When the polymerization is performed under clean conditions, the resulting copolymers are characterized by high end-group fidelity and Poisson-like molecular weight distributions with dispersities below 1.2. While pSar might be able to tackle most of the current concerns of poly(ethylene glycol) (PEG), *e.g.*, acute immune responses, the polypeptide part can provide a plethora of reactivity or functionality, allowing to tailor the polymer for specific tasks. In this review, we provide an overview on the origins of NCA polymerization and polypept(o)ides and provide a detailed overview on the last decade of research focusing on synthesis, characterization, and application. Arguably the biggest applicational progress for polypept(o)ides has been made in nanomedicine. Here, the remarkable combination of functionality, biocompatibility and a high degree of synthetic control has led to established protocols for the certified production of polypept(o)ides, which will enable the rapid clinical translation for the years to come.

1. Introduction

Polypept(o)ides have been introduced by Birke et al. in 2014 as hybrid materials combining the intrinsic functionality and stimuli-

Fig. 1. General chemical composition of polypept(o)ides, overview of polymeric architectures and resulting nanomedical delivery platforms.

responsiveness of polypeptides with polypeptoids, *e.g.*, pSar, for solubility and steric shielding [1–3]. Considering peptides and proteins are based on *α*-amino acids, Bartlett and co-workers defined peptoids as oligomers of *N*-substituted glycines that are connected by amide bonds in the main chain in 1992 [4,5]. The term was later expanded by Zuckerman and co-workers, referring to polypeptoids and peptoids for long and short sequences, respectively. In general, polypeptoids can be conceived as structural isomers of polypeptides [3,6]. Unlike polypeptides, polypeptoids generally lack the acidic hydrogen atom at the amide nitrogen and are thus exclusive hydrogen bond acceptors that do not form secondary structures unless specific substituents are introduced in the side chain [7–10]. The highly water-soluble pSar, poly(*N*-methyl glycine), is among the most intensively studied polypeptoids [11–13]. The free amino acid sarcosine can be found in muscle tissue and as a component of creatine (*N*-amidino sarcosine) in tissues with high energy demand [14–16]. Sarcosine can be synthesized from glycine *via* the enzyme glycine-*N*-methyl transferase and degraded by sarcosine dehydrogenase [17–19]. Therefore, polypept(o)ides can be synthetic polymers entirely based on endogenous amino acids [1–3]. While polypept(o)ides have already been used for surface modifications[12,20–22] and as surfactants [23,24], they are mostly applied as materials for diagnosis and therapy in nanomedicine. In the past decades, nanomedicine has evolved into a well-accepted tool for drug and gene delivery, or for imaging probes to visualize certain disease pathologies or disease-related biomarkers [25–27]. Several classes of therapeutic drug delivery systems have been developed and applied to multiple diseases including bacterial and viral infections, inflammation, and cancer. Especially over the last couple of years, polypept(o)ides have been receiving increasing attention as a new class of functional materials for the design of nanomedicines as indicated by an increase in publications and active development programs in pharmaceutical industry (Fig. 1) [28]. The process has led to the establishment of facilities for the production of polypept(o)ides under the standards of Good Manufacturing Practice (GMP) and culminated in the recent launch of the excipient Apisolex® for solubility enhancement of poorly soluble drugs by The Lubrizol Corporation [29,30].

The established synthetic methodologies provide access to various well-defined polymeric architectures leading toward functional approaches, especially in the field of nanomedicine. This review aims to elucidate the origins of polypept(o)ides, the current synthetic methods based on NCA polymerization, to present a system-

atic overview of the application of polypept(o)ides, and provide an outlook on future applications of these hybrid materials.

1.1. Polypeptides

Polypeptides, natural or synthetic, depict a class of polymers comprising *α*-amino acid repetitive units. Beside other strategies, the synthesis of polypeptides can also be performed by NCA polymerization, particularly whenever a precise sequence control is not warranted but high molecular weights intended. We would like to refer the interested reader to other excellent reviews on this subject [31–35].

1.2. Polypeptoids

Polypeptoids are defined as *N*-substituted polyglycines, that are connected by amide bonds in the main chain [4–6]. This class of materials has received increasing attention over the last decades, and polypeptoids have been subjected by excellent reviews [36–38]. Polypeptoids can be obtained by either solid phase synthesis as well as by ring-opening polymerization (ROP) of the corresponding NNCAs. Among these polypeptoids, pSar is particularly interesting. It is a non-ionic and highly water-soluble polymer that adopts a random coil conformation in aqueous solutions, attributable to the even population of the *cis* and *trans* conformation of the amide bonds [11,39–41]. Comparable to PEG, pSar solely acts as a weak hydrogen bond acceptor without any hydrogen bond donor properties, while being slightly less flexible when comparing the respective Kuhn lengths of $l_{k, \, pSar} = 1.5$ nm and $l_{k, \, PEG} = 1.1$ nm [11]. PSar matches the requirements for protein resistant surfaces summarized by the Whitesides' rules in 2001 [42]. Indeed, already Ostuni et al. described superior protein resistance of self-assembled monolayers functionalized with tri(sarcosine) since reduced levels of protein adsorption and cell adhesion were found [42,43]. These results were later confirmed by Messersmith and co-workers reporting excellent resistance of pSar-grafted titanium dioxide (TiO_2) surfaces toward non-specific adhesion of proteins or any attachment of mammalian or bacterial cells [12]. Moreover, Jordan/Luxenhofer and co-workers investigated the resistance of inorganic surfaces to biofouling after modification with polypeptoid brushes [20,22]. These experimental findings are further supported by molecular dynamics simulations, in which PEG and pSar showed an equally low affinity for interaction with human serum

Scheme 1. Nucleophilic amine-initiated polymerization of NCAs and NNCAs.

albumin [44]. Moreover, while neither pSar or PEG triggers the complement cascade, acetylation of the pSar terminal amine is generally recommended for its beneficial effect in minimizing complement system responses [11,24]. Consequently, pSar can be classified as a "stealth"-material and has emerged as a potential substitute for PEG in medical applications when increased water solubility and reduced immunogenicity and mononuclear phagocyte system (MPS) recognition are desired [3,11]. The search for alternatives to PEG was specifically boosted by the detailed study of potentially PEG-related side-effects and increased number of anti-PEG antibodies after vaccination with lipid nanoparticle-based SARS-CoV-2 vaccines [45,46].

1.3. Polysarcosine in nanomedicine

The qualification of pSar as an alternative material in medical and medicinal applications has been explored over the past decades and is now rising as a new star. As an early example, in 1985, Moran and co-workers reported that covalent conjugation of pSar to grass pollen allergens decreased the immunoglobulin E (IgE) formation [47,48]. More recently, pSar attracted increasing attention as an alternative material to PEG and has been investigated for shielding of antibody-drug-conjugates [49,50], proteins [51], liposomes [24,52], inorganic nanoparticles [53], and lipid nanoparticles [54,55]. In 2020, Son et al. prepared PEG and pSar functionalized liposomes and compared the immune response after intravenous administration to rats [52]. As a result, significantly higher levels of IgM and IgG antibodies were found for the PEGylated liposomes. Hereafter, the second administration revealed the accelerated blood clearance (ABC) phenomenon for PEGylated liposomes, while pSar functionalized liposomes retained identical circulation half-lives upon repeated administration. For lipid nanoparticles (LNPs), both, PEG-lipids and pSar-lipids yielded similar mRNA nanocarriers, whereby reduced cytokine secretion and lower immunogenicity were found for the pSar-containing LNPs [54]. In summary, pSar has emerged as a biocompatible polymeric material suitable for medicinal applications [56]. Since our review focuses on polypept(o)ides, thus combinations of pSar with polypeptides, we refer the interested reader to the review by Birke et al. for combinations of pSar with lipids and other polymers [3].

2. Polypept(o)ides

Synthetic polypept(o)ides can be conveniently prepared by living amine-initiated ROP of NCA/NNCA [57–59]. Despite early attempts by Bailey et al. [60], NCA polymerization does not offer control on the primary amino acid sequence, making it a complementary tool distinct from solid-phase peptide synthesis or recombinant peptide expression techniques [61–63]. A general scheme for the amine-initiated polymerization of NCAs or NNCAs ($R^1 \neq H$) is given in Scheme 1.

### 2.1. Polypept(o)ide architectures

Depending on the desired application, polypept(o)ides can be designed with block-wise primary sequences, linear or branched architectures, featuring a Poisson-like molecular weight distribution [2,3]. The various architectures of polypept(o)ides are illustrated in Fig. 2A, the most studied NCA monomers are shown

in Fig. 2B, and the functional end-groups are summarized in Fig. 2C. Besides block-wise construction of copolypept(o)ides by sequential polymerization of NCAs and NNCAs, in 2015 Klinker et al. firstly demonstrated their preparation by chemical ligation techniques utilizing functional initiators and complementary end-group modifications for the ligation of different homopolymers [64]. The extension from di- to triblock copolypept(o)ides by sequential polymerization was introduced by Heller et al. in 2015, with ε–*tert*-butyloxycarbonyl-l-lysine (Lys(Boc))-NCA, ε-trifluoroacetamide-l-lysine (Lys(TFA))-NCA and sarcosine-NCA [65]. Just recently, the synthesis of triblock copolypept(o)ides could also be demonstrated utilizing a bifunctional initiator approach, which was introduced earlier to construct diblock structures, further enabling the incorporation of functional groups between the blocks [66,67]. Reaching out to more complex architectures than linear polymers, in 2015, Hörtz et al. presented the synthesis of molecular polymer brushes based on polypept(o)ides which emerged from a grafting-from approach utilizing poly(*N*-(6-aminohexyl)methacrylamide) (PAHMA) and pLys backbones for NCA/NNCA polymerization [68]. Moreover, polymer brush architectures from a grafting-onto approach have been described by Stéen et al. in 2020 [69]. Investigating the broad variety of small molecular structures with multiple amine functions as initiators, access was found to polymeric star-architectures. In 2017, 3- and 6-arm star-like polypept(o)ides have been introduced by Holm et al., followed by A_3B and AB_3-type miktoarm analogues by Schwiertz et al. in 2020 [70–72]. Access to AA'B- and ABC-type miktoarm architectures has been demonstrated by Capelôa et al., introducing a lysine end-group to a pSar chain, comprising two amine functions with orthogonal protective groups [73]. In 2020, Skoulas et al. first demonstrated polypept(o)ide-based 8-arm star-like architectures [74]. Utilizing lysine dendrimeric structures, the Ashford lab was able to create star architectures with up to 32 arms as well as telodendrimeric polypept(o)ides in 2020 and 2022, respectively [75,76]. As a consequence of providing access to functional materials of defined polymeric architecture and narrow molecular weight distribution by NCA polymerization, polypept(o)ides have attracted increasing attention [2,3]. The latest developments for medicinal applications will be discussed in the paragraph *Polypept(o)ides in Nanomedicine.*

2.2. Origins of polypept(o)ides and (N)NCA polymerization

The term polypept(o)ides was coined by Birke et al. in 2014 referring to the new class of polymeric materials combining polypeptides with polypeptoids [1,2]. Early examples of polypeptide/polypeptoid copolymers, however, date back to the 1950s, *viz.* the origins of NCA and NNCA polymerization, when studying fundamental properties and reaction kinetics was the major focus of research [35,77]. Besides early exploration of block copolypept(o)ides, also copolypept(o)ides have been synthesized and studied, aiming to understand the structure and function of the synthetic polypeptides and their natural analogs [78–80]. Considering medical applications, Kimura and co-workers investigated polypept(o)ides in the 1990s [81–85]. Among others, microcapsules were prepared from pSar-*b*-poly(ε-benzyloxycarbonyl-l-lysine) (pSar-*b*-pLys(Z)), pSar-*b*-poly(γ-methyl-l-glutamate) (pSar-*b*-pGlu(OMe)), and pSar-*b*-poly(ʟ-alanine) (pSar-*b*-pAla), and the release of fluorescein isothiocyanate (FITC)-dextran was determined, including release upon different triggers like pH or temperature and loading of hydrophobic drugs. The first detailed proof for the controlled polymerization of polypept(o)ides with high molecular weights was provided by Birke *et al.* in 2014. In this work, applications in drug formulations or as surfactants in emulsion polymerization was described [1]. The first NCA synthesis was discovered by Hermann Leuchs in 1906, and NCAs are thus also called

A) Polymeric Architectures

Bifunctional Initiator Approach
Holm *et al.* 2015 (Diblock)
Capelôa *et al.* 2022 (Triblock)

Sequential Copolymerization
Birke *et al.* 2014 (1st Polypept(o)ides)
Heller *et al.* 2015 (Triblock)

Pept(o)Brushes by Grafting-to
Stéen *et al.* 2020

Pept(o)Brushes by Grafting-from
Hörtz *et al.* 2015

Symmetric Pept(o)Stars
Holm *et al.* 2017 (3-Arm)
Holm *et al.* 2019 (6-Arm)
Skoulas *et al.* 2020 (8-Arm)

Dendrimer Polypept(o)ides
England *et al.* 2020

Asymmetric Pept(o)Stars
Schwiertz *et al.* 2020 (A₃B & AB₃)
Capelôa *et al.* 2023 (AA'B & ABC)

B) Building Blocks

Monomers:

X = H, CH₃
R = H, CH₃

Initiators:

Primary or secondary amines.

All natural and unnatural amino acids can be converted to monomers.
Protecting groups required for -OH, -SH, -NH₂, and -COOH groups.

C) Functional End-Groups

for Click Chemistry:

for Chemistry & Targeting:

sugar moiety

Introduction via initiator or *in situ* modification of the amine end-group
with anhydrides, acyl halides, reactive esters, or carboxylates.

Fig. 2. A) Summary of synthetic strategies to access various polypept(o)ide architectures by amine-initiated ROP of NCAs/NNCAs, including B) an overview of common amino acid-based building blocks and initiators as well as C) introduced functional end-groups. Seminal publications of these synthetic approaches to yield well-defined polymeric architectures are assigned.

Leuchs' anhydrides [35,86]. A summary of important milestones on the origin of NCAs and polypept(o)ides is displayed with a timeline in Fig. 3.

In the initial publication, Leuchs obtained glycine NCA upon heating of *N*-ethoxycarbonyl glycine chloride (Schee 2A) [86]. Moreover, Leuchs carefully described the release of CO_2 after the reaction of the NCA with water at room temperature, whereby an insoluble product was formed, which was interpreted as a higher anhydride of glycine. Leuchs further applied the methodology to other amino acids, including phenylalanine, leucine, and *N*-phenyl glycine yielding comparable NCAs and reaction products [87,88]. Despite the seminal publication from Hermann Staudinger in 1920, the general concept of polymerization and macromolecules was not completely established and still debated at that time [35,89]. Early reports on NCAs thus mainly focused on the analysis of the degradation products of NCAs, *e.g.*, diketopiperazines and hydan-

toins, and referred to so-called higher condensed anhydrides for products with higher molecular weights [90–92]. Sigmund and Wessely described the first synthesis of sarcosine NCA in 1926 [93]. Herein, the authors mention polypeptides as possible products of the reaction of sarcosine NCA with pyridine, yet still refuse to describe these as polymers rather referring to higher condensed anhydrides. These findings were later revised by Meyer and Go in 1934, detecting no differences between the higher condensed anhydrides derived from NCA polymerization compared to other polypeptides in X-Ray analysis, establishing the connection between NCAs and polypeptides [91,94]. In 1947, Woodward and Schramm claimed the first intended NCA polymerization using traces of water for the initiation of the reaction in benzene-solutions yielding polypeptides as synthetic analogs of proteins [95]. In the following years, various polypeptides have been synthesized from this methodology and studied for their physico-

Fig. 3. Origins of NCA & NCCA synthesis and polymerization leading towards the intended synthesis of polypept(o)ides. Important milestones for discovering NCAs and understanding NCA polymerization for the synthesis of polypept(o)ides are given.

Scheme 2. A) Synthetic pathway to glycine NCA described Hermann Leuchs and B) the NCA synthesis according to the Fuchs-Farthing method.

chemical properties [13,77,79]. The kinetics of the NCA polymerization was first examined by Waley and Watson, revealing a first-order reaction for the polymerization of sarcosine NCA in nitrobenzene [96–98]. Earliest examples for polypept(o)ide copolymers can be found from Hanby, Waley, and Watson who briefly described the synthesis of pSar-*block*-poly(DL-phenylalanine) in 1950, yet, comprehensive study design and characterization of the copolymer was provided later by Bamford and Ballard in 1956 [99,100]..

To generate NCAs and NNCAs, Fuchs suggested the direct reaction amino acids with phosgene, which was refined and improved by Farthing (Scheme 2B) [101,102]. Addressing safety concerns and facilitating the application, gaseous phosgene can also be substituted by liquid diphosgene, or solid triphosgene, whereby phosgene is generated *in situ* [103,104]. Despite a large variety of routes to (N)NCAs, the Fuchs-Farthing method is the preferred synthetic route to (N)NCA monomers, allowing for larger scales, high yields and sufficient monomer purity after sublimation and/or repetitive recrystallization [3,105]. Nevertheless, alternative approaches aiming for high monomer purity have been presented more recently. Laconde et al. reported on the synthesis of NCAs and NNCAs using Boc-protected amino acids and *n*-propanephosphonic acid anhydride (T3P) yielding numerous products with high melting points [106]. Toshiyuki et al. reported on the photo-on-demand synthesis of NCAs by light-induced reaction of amino-acids with oxygen and chloroform, thus representing an *in situ* phosgenation approach [107]. Of note, the purity of all reagents, *i.e.*, monomer, solvent, and initiator, is of major significance for successful NCA polymerization. Beyond characterization of NCAs by nuclear magnetic resonance (NMR) spectroscopy, special attention should be devoted to determination of melting points [105], Karl-Fischer-Titration to determine residual water content in monomers and solvents, and ion chromatography to detect inorganic contaminations, *e.g.*, nu-

cleophilic chloride ions, to limit the occurrence of side reactions during the NCA polymerization [108–110].

2.3. NCA polymerization

From a mechanistic understanding, two competing reaction pathways exist in parallel, namely, the activated monomer mechanism (AMM) and the normal amine mechanism (NAM). In the NAM, the amine initiator solely acts as a nucleophile attacking at C-5, while deprotonation of the NCA takes place within the AMM. For more details on mechanistic pathways and potential side reactions we would like to refer the interested reader to detailed reviews by Birke et al. and Hadjichristidis and co-workers [3,111]. Of note, living amine initiated polymerization of NCAs is only possible for the NAM pathway, whereby Poisson-like molecular weight distributions can be obtained, when the initiation is faster than the propagation reaction [2,111]. Since NNCAs do not contain an acidic proton at the nitrogen atom the AMM pathway is generally inhibited for polypeptoids. *Vice versa*, the polymerization of NCAs is easily affected by the nucleophilic or basic character of the initiator [2,35,111]. In addition and comparable to other living polymerization techniques, also NCA/NNCA polymerization is highly sensitive to impurities since these may promote the AMM pathway, catalyze side reactions, and initiate or terminate the chain growth [105,111,112]. In 1997, Deming reported on the living NCA polymerization by using zero-valent nickel amido-amidate complexes initiating and mediating the chain growth reaction [113]. Herein, homo- and block copolypeptides of poly(γ-benzyl-l-glutamate) (pGlu(OBn)) and pLys(Z) could be synthesized with high molecular weights and narrow dispersity ($Đ < 1.2$). Deming further expanded the concept to cobalt and iron complexes, and synthesized library of functional polypeptides [34,114].

Fig. 4. Polymer analysis demonstrates clean NCA polymerization with complete block initiation and end-group fidelity. GPC elugrams in hexafluoroisopropanol (HFIP) of A) pSar-*b*-pGlu(O*t*Bu) diblock copolymers with varying chain lengths and pGlu(O*t*Bu) precursor (Reprinted with permission from Yoo et al. [119]. © 2018 American Chemical Society), and B) pSar-*b*-p(DL)Cys(SO$_2$Et)-*b*-pGlu(OBn) triblock copolymers and respective precursors, (Reprinted from Bauer et al. [120]. with permission). C) MALDI-TOF MS analysis of end-group modified pSar polymers as proof of end-group integrity (Reproduced from Klinker et al. [64]., © 2015, with permission from the Royal Society of Chemistry).

However, polymerization of NNCAs was not substantiated until recently since initiation required an acidic proton for β-hydride elimination. The Kramer group thus improved the Ni and Co initiators allowing for polymerization of proline NCA [115]. Nevertheless, elaborate synthesis and potentially remaining traces of toxic heavy metal ions may hamper this technique [2]. In 2004, the groups of Schué and Hadjichristidis reported that reaction temperature, sufficient removal of CO$_2$, and the purity of the components, are the key parameters for the living amine-initiated polymerization of NCAs, which from our point of view can already ensure the controlled living polymerization of various NCAs until degree of polymerization of 100–200 [57,58]. In the following years, several groups contributed to expanding the living amine-initiated NCA polymerization leading to a robust and well-established type of polymerization [1,59,116–118].

With access to conditions for living amine-initiated NCA polymerization, *i.e.* featuring active end-group integrity of the resulting polymers, sequential polymerization of different NCAs/NNCAs was enabled with the absence of homopolymer-forming side reactions and maintaining Poisson-like molecular weight distribution with low dispersity. Exemplarily, consistent and controlled chain extensions to yield pSar-*b*-poly(γ−tert−butyl−L−glutamate) (pSar-*b*-pGlu(O*t*Bu)) or pSar-*b*-poly(*S*-ethylsulfonyl-D,L-cysteine)-*b*-pGlu(OBn) (pSar-*b*-p(DL)Cys(SO$_2$Et)-*b*-pGlu(OBn)) block copolymers were nicely visualized by Yoo et al. and Bauer et al., respectively, utilizing gel permeation chromatography (GPC) presenting clean shifts of the elugrams towards lower elution volumes upon block addition (Fig. 4A,B) [119,120]. Moreover, active end-group fidelity

paired with the tolerance of functional initiators, allows for the installation of diverse functional groups at one or both ends of the synthesized polymer, as already indicated in Fig. 2. Klinker et al., for example, demonstrated quantitative end-group integrity of pSar polymers by, among others, utilizing a dibenzocyclooctyne (DBCO)-functionalized initiator or *S*-benzyl thiosuccinic acid for end-group attachment, confirmed by matrix-assisted laser desorption/ionization time-of-flight mass spectroscopy (MALDI-TOF MS) (Fig. 4C) [64].

At present, the slow propagation rates of NCA/NNCA ROP remain a limitation. Current research thus aims to accelerate the reaction rates of the polymerization to achieve chain lengths beyond 1000 [31]. In particular, organocatalysis techniques were therefore applied to NCA polymerization. As early as 1954, Ballard et al. explored the use of organic acids as catalysts [121], which have seen a recent renaissance due to their benign nature and widespread availability. Recently, Zhang et al. and Lu et al. have showcased the substantial enhancement of the propagation rate of *N*-thiocarboxyanhydride, NCA and NNCA polymerizations in DCM with organic acids such as acetic acid, respectively [122–124]. In 2019, Zhao et al. combined 1,3-bis(2-hydroxyhexafluoroisopropyl)benzene (1,3-bis-HFAB) and *N,N*-dimethyl ethanol amine in dichloromethane (DCM) to activate the NCA monomer by hydrogen bonds [125]. Moreover, Xia et al. demonstrated accelerated polymerization in DCM upon the addition of crown ether as a catalyst [126]. With a view towards biomedical applications, large molecular weights are often not necessarily an advantage or simply not needed, since nanosized struc-

Fig. 5. A,B) GMP facility for the certified production of polypeptides, polypeptoids and polypept(o)ides, C) Fishbone or Ishikawa diagram for the identification of internal and external factors affecting CQAs based on ICH Q9 "Quality Risk Management" and Q11 "Development and Manufacture of drug substances". Adapted to the polypept(o)ide manufacturing process from Glodek et al. [137].

tures can be obtained by solution self-assembly. Nevertheless, fast and robust mechanisms facilitating large-scale production will aid translation of polypept(o)ides, and organocatalysis represents a promising tool for chemists. For extended information on current developments in NCA polymerization techniques, we would like to refer the interested reader to reviews by Song et al. and Raisines Mazo et al. [31,32].

2.4. Certified production of polypept(o)ides

Over the last years, more than 10 published patents have protected various polypept(o)ides as well as their use in various pharmaceutical applications, *e.g.* as mRNA delivery systems, drug excipients or core-crosslinked polymer micelles [127–136]. Nevertheless, the progress of polypept(o)ide-based therapeutics from early research and development programs to clinical phases and eventually marketed products relies inevitably on the certified production of the materials to be used as regulatory ready precursors, excipients or drug substances in nanomedicine-based drug products. This implies a comprehensive approach from initial technology transfer, process and analytical development in feasibility programs, to process scale-up, and final transfer of protocols for GMP implementation and GMP-compliant batch production. In this industrialization and manufacturing process development, the Technical Requirements for Pharmaceuticals for Human Use given by the International Council for Harmonization (ICH) have to be considered to secure approval from regulatory authorities. Of particular relevance are the Quality Guidelines, so-called ICH-Q. Recent progress made in the validation of analytical methods for the characterization of macromolecules has enabled drug developers and manufacturers to establish the adequate control strategy for Chemistry, Manufacturing and Control (CMC) development of these materials following ICH-Q2 "Analytical validation" guidelines. This has allowed the identification of critical process parameters (CPPs) and establish in-process controls (IPCs) for a robust and reproducible manufacturing process of polypeptides, polypeptoids, and polypept(o)ides. In order to guarantee target acceptance criteria are met during

the process, a normalized operational range (NOR) of the CPPs is usually established. This is defined and adjusted by previous PAR (proven operational range) studies where parameters such as concentration, temperature, reaction time, purification and drying, hold times within the process operation units, and the stability of the product & intermediates during these are stressed to identify the CPPs. Critical Quality Attributes (CQAs) of polypept(o)ides must be defined at the beginning of the process and will depend on the particular manufacturing, dosage, indication, administration route, and regulatory classification (excipient, raw material or key intermediate for further manufacturing, excipient and drug substance). Fishbone or Ishikawa diagrams are a useful and illustrative approach to outline all parameters affecting the CQAs (Fig. 5) [137]. These representations summarize the steps in the manufacturing process, highlighting possible quality control issues and defining resources and action plans based on the ICH-Q9 "Quality Risk Management" and Q11 "Development and Manufacture of Drug Substances" guidelines. Basic CQAs for polypept(o)ides have been established and are identity, purity, Mw distribution & polydispersity, enantiomeric excess in case of the introduction of chiral monomers, ratio of monomers in case of multiblock copolymers, counterion content for polyelectrolytes, impurities profile (whether there are raw materials, process or degradation related and solvents) and bioburden.

Although, the overall number of companies being currently able to provide with GMP compliant supply of polypept(o)ide-based delivery systems is limited, these materials are available in certified grade and can support drug development innovators in their clinical development journey from preclinical/clinical trials to commercialization.

3. Nanomedicine

Since most of the applications of polypept(o)ides are in the area of nanomedicine, we feel that a brief introduction in the related needs is valuable for readers. The term nanomedicine refers to the application of nanotechnology in medicine to improve diagnostic

Fig. 6. Idealized perspective on chemotherapy without and with the use of nanomedicines. Created with BioRender.com.

and therapeutic efficacy for patient compliance. In nanomedicine, nanoparticles serve as tools for drug delivery, are drugs themselves, and improve or enable *in vivo* or *ex vivo* disease diagnosis [138–144]. Following the guidelines of the International Organization for Standardization (ISO) and the Commission of the European Union, nanoparticles are objects of any shape with at least one external dimension in the range of 1–100 nm [145–147]. Nanoparticles offer the potential to modify the pharmacokinetic profile of active pharmaceutical ingredients (APIs) without editing the structural entities required for the mode of action [148–150]. Administration, distribution, metabolism, and excretion (ADME) can be altered and governed by the nanoparticle enhancing specificity and bioavailability of a given drug opening or extending the therapeutic window [146,151,152]. The nanocarrier design follows the structural demands of the API while referring to the intended application [153–156]. For nucleic acid delivery as required for BioNTech's and Moderna's Covid-19 vaccine, protection of the sensitive cargo to enable release of the intact mRNA into the cytosol of immune cells is of significance and featured by LNPs [157–160]. Nanomedicine thus opened the therapeutic window for RNA-based therapies substantially [161–163]. *Vice versa,* for small molecule APIs used in cancer therapy, nanomedicine aims to provide solubility and reduce the large volume distribution caused by the unspecific diffusion of the low molecular weight compounds [143,164,165]. Despite being highly potent in the mode of action, many small molecule APIs are hydrophobic and require excipients and high dilutions for administration [149,166–168]. Approved for medical use in 1993 and 1996, the formulations of paclitaxel using ethanol and Cremophor EL (Taxol), and docetaxel with polysorbate 80 (Taxotere) are among the most successful drugs for adjuvant chemotherapy [165,169,170]. Nevertheless, anaphylactic reactions, hypersensitivity, hemolysis, and peripheral neuropathy are common side effects attributed to these excipients [171,172], which restricts the maximum tolerated dose, while prolonged administration times limit patient compliance [171,172]. In this case, nanomedicine aims to provide solubility and a selective distribution profile to APIs to reduce off-target toxicity and improve therapeutic success [141,173,174].

Following the ambitions of nanomedicine shown in Fig. 6, a large variety of nanoparticle therapeutics has been developed to improve the pharmacokinetic profiles of APIs. Initial investigations

date back to 1954 when Horst Jatzkewitz reported on mescaline coupled to a copolymer of vinylpyrrolidone and acrylic acid *via* an enzymatically cleavable peptide linker [156,175–178]. In consecutive *in vivo* studies a sustained drug release was observed [176]. Mescaline could still be detected in urine after 17 days, compared to 16 h for the free drug, whereas no traces were found after direct conjugation without the cleavable section [176]. Jatzkewitz clearly described the potential of polymer-drug conjugates to alter the pharmacokinetics of APIs and should be recognized for his groundbreaking work [175,176]. The idea for polymer drug-conjugates was later refined and conceptualized by Helmut Ringsdorf considering solubility, drug conjugation, and targeting [156,179].

Beyond polymer-drug conjugates many different nanocarriers have been designed and evaluated in (pre-)clinical investigations [142,149,150,178,180,181]. A schematic overview is shown in Fig. 7 [26,180]. The encapsulated or conjugated small molecule APIs are typically in the range of 0.1 to 1.0 nm in hydrodynamic diameter and are displayed as red (hydrophobic drugs) and green (hydrophilic drugs) stars as well as RNA/DNA [180].

The drug delivery systems can be generally divided into molecular and self-assembled structures and have been optimized for a broad variety of therapeutic cargos and diagnostic probes [153,178,182]. In particular self-assembled nanoparticles are characterized by their core-shell architecture and can be readily formed from amphiphilic lipids or polymers [183–185]. Lipophilic drugs can be encapsulated in the hydrophobic membrane or core compartment, while the hydrophilic corona provides steric shielding to reduce or prevent recognition by the immune system [185–187]. Likewise, hydrophilic polymers are used for shielding of molecular nanocarriers, *e.g.*, to increase the blood circulation half-life and reduce the immunogenicity of proteins [178,188,189]. While PEG is still the most frequently used polymer, the polypeptoid pSar reduces the immunogenicity even further. For therapeutic inventions using hydrophobic small molecule APIs, polymeric micelles (PMs) are among the most promising carrier types [187,190–192]. Herein, the core compartment allows for drug loading and can be designed and adjusted for the conjugation of (pro-)drugs featuring stimuli-responsive release [193–198]. Polymersomes and liposomes further allow for encapsulation of hydrophilic drugs in the aqueous core pocket, while additional stabilization is still essential for membrane-permeable drugs such as doxorubicin [150,199–

Fig. 7. Schematic overview of the most common drug delivery systems in nanomedicine with approximate hydrodynamic diameters. Small molecule drugs are represented by red (hydrophobic) and green (hydrophilic) stars, RNA/DNA, drug linkers by dark green rectangles.

202]. In contrast, polyplexes and LNPs comprise a cationic polymer block or cationic lipid for charge-induced complexation and have been designed as non-viral vectors for gene therapy to provide protection and stimuli-responsive release for RNA or DNA [21,159,162,178,203]. Besides lipid and polymer-based nanocarriers, inorganic nanoparticles, colloids, and metal-organic frameworks have been established for drug delivery and diagnosis [26,204–207].

3.1. Physiological barriers for nanomedicine

On the journey to the target site, nanomaterials face several barriers and obstacles for successful drug delivery [138,208,209]. In general, the majority of nanocarriers are applied by parenteral administration routes [210–212]. Activation of the adaptive immune system typically follows intramuscular injection for addressing transport into the draining lymph node [213–215]. In contrast, for cancer therapy, nanomedicines are mainly administered by intravenous injection aiming to target metastasis as well as the primary tumor site [216–218]. Injection into the bloodstream exposes the nanocarriers to the blood components, *e.g.*, red blood cells, immune cells, and plasma proteins, as well as to dilution [219–222]. Stabilization and shielding strategies are thus required to prevent unspecific complement activation, opsonization, and recognition by the MPS [138,186,222,223]. The MPS consists of bone marrow progenitors, monocytes, and tissue macrophages located in organs such as the liver and spleen [223,224]. Intended to remove foreign material from the bloodstream, non-specific accumulation in these organs is a major obstacle for nanomedicines that impedes drug delivery to the diseased target site (Fig. 8) [224,225].

Strategies to avoid rapid clearance comprise the decoration of nanocarriers with hydrophilic polymers, such as PEG, poly(2-oxazoline)s or pSar, which follow the Whitesides' rules for protein-resistant materials and reduce MPS recognition, phagocytosis, and clearance from the circulation [2,24,42,226,227]. Mechanistically, the enhanced repulsive forces among the hydrated polymer strands form an impermeable coating preventing van der Waals, electrostatic, and hydrophobic interaction with proteins [186,228]. Following PEG as the gold standard material, the term "PEGylation" was coined for the surface modification of materials with PEG, attributing reduced recognition properties ("stealth"-effect) [188,229,230]. Herein, the molecular weight of the hydrophilic polymer significantly influences the shielding efficiency [228]. Consequently, the PEG chain length was carefully optimized for the development of Doxil (doxorubicin sulfate nanocrystals, encapsu-

lated in stealth liposomes with a lipid bilayer of a high melting point (T_m = 53 °C)), and PEG$_{2k}$(DP=50)-lipid (lipid: 1,2-distearoyl-sn–glycero-3-phosphoethanolamine; DSPE) was selected considering circulation time and lipid metabolism [150]. For block copolymer micelles, Kwon et al. reported that PEG$_{12k}$ (DP=270) significantly reduced the nanoparticle clearance compared to shielding by PEG$_{5k}$ (DP=120), resulting in a 5-fold increase of nanoparticles in circulation after 4 h post-injection [231,232]. These results underline that polymer chain lengths between 50 and 300 are particularly interesting.

Beyond the surface properties, the hydrodynamic diameter is an important parameter affecting the biodistribution of nanoparticles. Large particles with hydrodynamic diameters > 200 nm can be rapidly recognized and cleared *via* the MPS in the liver and spleen [154,156,187]. Contrariwise, glomerular filtration in the kidneys defines the lower size limit for nanoparticles that aim for long blood circulation [138,233]. Threshold values for rapid renal excretion were found as ≤ 5.5 nm for quantum dots, approx. 29 kDa for dextran, and around 30 kDa for linear PEG [234–236]. Conversely, to avoid long-term side effects such as storage diseases, the renal filtration sets an important limit for the maximum size of the individual nanocarrier components if the material is not biodegradable within relevant time frames [175,230,237]. Having a biodegradable stealth-like polymer would therefore be highly advantageous.

3.2. Tumor targeting by the EPR effect and beyond

The discovery of the enhanced permeability and retention (EPR) effect supported the field of nanomedicine, giving a rationale for targeting nanoparticles to inflamed and tumorous tissue [164,238,239]. In 1984, Maeda et al. found an increased concentration of neocarzinostatin (NCS) in the tumor tissue of rabbits and mice when NCS was conjugated to a styrene-maleic acid copolymer (SMANCS) [240]. After detailed elucidating studies in tumor-bearing mice using ^{51}Cr-labeled proteins of varying molecular weights in 1986, Matsumura and Maeda then accounted the unique vascular characteristics of the tumor tissue for the specific accumulation of macromolecules therein [241]. Due to extensive and rapid proliferation, the cancer vasculature shows a high tendency for deficient vessel structures leading to fenestrations with higher permeability for nanoparticles compared to normal tissue [178,241,242]. Moreover, insufficient lymphatic drainage reduces nanoparticle clearance from the tumor retaining the accumulated particles [241]. Consequently, if unspecific excretion and interaction with the MPS can be prevented, passive accumulation of the

Fig. 8. Intravenously administered nanoparticles encounter non-specific interaction with the MPS. The intensity of the turquoise color refers to the nanoparticle uptake within each organ. The reduced flow rates in the liver sinusoid facilitates nanoparticle uptake by the residing immune cells, *e.g.*, Kupffer cells. Created with BioRender.com.

nanocarriers can be achieved [167,178,243]. This passive accumulation correlates with the circulation time of nanoparticles and *vice versa*, which in turn underlines the importance of stealth-like polymers in nanomedicine.

Nevertheless, the EPR effect has been critically discussed, and cannot be seen as a general concept for all tumor types [164,244–247]. As such, the EPR effect was reported to be more prominent in murine (xenograft) tumor models compared to human patients [248,249]. Moreover, a large heterogeneity in EPR susceptibility was observed among cancer patients calling for personalized medicine and patient stratification before applying nanomedicines as a general treatment regimen [250,251].

From the methodical viewpoint, more detailed investigations on the tissue level recently enlightened the actual targeting mechanism providing an deeper understanding and defining the basis for future therapeutic concepts [209,252–254]. Herein, Chan and co-workers employed PEGylated gold nanoparticles to investigate the exact mechanism accounting for nanoparticle entry into tumor tissue [255,256]. Despite minor fractions of particle accumulation *via* passive diffusion, active transport mechanisms were described as the main driving force for nanoparticle entry into tumor tissue for a variety of tumor models [255]. Moreover, a specific type of endothelial cells, nanoparticle transport endothelial cells (N-TECs), was identified as a gatekeeper for the transport process [256]. On the other hand, Biancacci et al. combined optical whole-animal imaging by micro-computed tomography-fluorescence tomography (µCT-FLT) with immunohistochemistry for a detailed biodistribution analysis of dye-labeled core cross-linked polymeric micelles [257]. On the organ level, 18.6 % ID/g of the injected dose (ID) were located within the tumor tissue, exceeding the doses found in the liver and spleen (9.1 % and 8.9 % ID/g). Interestingly, within the tumor microenvironment, 67 % of the nanoparticles were found in macrophages and other immune cells, although cancer cells accounted for 71 % of the overall cell population [257]. This underlines the potential of nanomedicine for therapies combining chemotherapy and immune modulation [253,257–260].

4. Polypept(o)ides in nanomedicine

Since the term polypept(o)ides was coined in 2014 and first reviewed by Klinker *et al.* in 2015, several polypept(o)ide-based polymer and nanoparticle architectures and assembled constructs have been established and investigated for therapeutic applications [2]. In these systems, the hydrophilic pSar provides the desired solubility and prevents recognition of the structures by the MPS, while the polypeptide section can be selected and tuned for drug or gene delivery [2]. As polypept(o)ides are easily accessible by the mild chemical conditions of the NCA/NNCA polymerization, a large variety of polymeric architectures has been synthesized, and functional side- or end-groups were introduced and exploited for cross-linking, API incorporation, and addition of targeting motifs [2,3,33,64,261,262].

4.1. Polymeric micelles

In their initial publication from 2014, Birke et al. reported that for pSar-*b*-pGlu(OBn) and pSar-*b*-pLys(Z) of elevated molecular weights, the succession of the block copolymerization (block sequence) is not relevant for the properties of the final block copolymers, and polymers with precise control over molecular weight and narrow dispersity ($Đ < 1.2$) can be obtained in all cases [1]. The amphiphilic copolymers were then applied for stabilization of organic colloids and for encapsulation of small molecules like paclitaxel[263] or the adenylate cyclase (cAMP) inhibitor MDL-12.330A in PMs [1,264]. Just recently Johann et al. demonstrated the potential of the cAMP inhibitor-loaded PMs, formed by dual-asymmetric centrifugation (Fig. 9A). Herein, MDL-12.330A (Fig. 9B) is stabilized in the micelle core by π-π-interactions with the aromatic benzyl groups [1,265]. Peritumoral injection of loaded PMs presented dose-depended suppression of cAMP levels within the melanoma tissue, leading to reduced tumor growth (Fig. 9C). Importance of immune infiltration could be demonstrated by non-effective treatment of adaptive immune cell-depleted mice (DEREG). Combinatorial treatment then achieved full tumor rejection and long-term immunity (Fig. 9D) in a B16F10 melanoma model, which underlines both, the remarkable potency of this approach and the often underestimated potential of small molecules for tumor immune therapy. Furthermore, mild synthetic conditions of the applied sequential NCA ROP enabled the use of a mannose-containing initiator, leading to mannose-decorated micelles. Uptake into DC 2.4 and bone marrow-derived dendritic cells (BMDCs) was increased and discovered to be mannose-receptor depended, indicating an active targeting approach [262].

Besides an application in tumor-immune therapy, pSar-*b*-pGlu(OBn) PMs have been employed to encapsulate pretomanid derivatives for tuberculosis therapy. The antibiotic-loaded PeptoMicelles showed remarkable stability in water, blood plasma, and lung surfactant as demonstrated by fluorescence cross-correlation

Fig. 9. A) Illustration of micelle formulation and drug loading by dual-asymmetric centrifugation. B) Chemical structure of MDL-12.330A. C) Inhibition of B16 melanoma growth by peritumorally injected MDL-loaded (red, $n = 6$)/non-loaded (blue, $n = 5$) micelles in C57BL/6 mice (as mean from three independent experiments). D) Similar to C) with DEREG mice and additional treatment with diphtheria toxin (DT) at day 7, 14 an 18 (arrows) (as mean from two independent experiments). Reprinted with permission from Johann et al. [265]., © 2021, with permission from Springer Nature.

spectroscopy and displayed prolonged circulation times of several days in zebrafish larvae and mice [266]. The most efficacious PeptoMicelle formulation eradicated the bacteria at non-toxic doses in the zebrafish larvae infection model and significantly reduced bacterial burden and inflammatory responses in the lungs and spleens of infected mice, which underlines the potential of core cross-linking of micelles by non-covalent π-π-interactions [266].

The combination of pSar with functional polyglutamic acid derivatives further led to micellar structures enabling simultaneous encapsulation and cross-linking by metal-based drugs. Herein, cisplatin was integrated into a polypept(o)ide-based delivery system resembling NC-6004 that was developed in the Kataoka lab using PEG-*b*-pGlu(ONa) [243,267,268]. As reported recently by Siemer et al., masking cisplatin in polymeric micelles of pSar-*b*-pGlu(ONa) resulted in a well-tolerated nanomedicine that enabled an alternative endocytic cell-uptake mechanism which mediated effective toxicity for LRRC8A-downregulated tumor cells circumventing cisplatin resistance [269]. Beyond platinum-based metal drugs, light-sensitive ruthenium(II) complexes granted fabrication of photocleavable PMs, demonstrating enhanced circulation times *in ovo* and releasing the drug upon irradiation as an external stimulus [270]. To reversibly conjugate ruthenium(II) complexes, the polyglutamic acid block was modified with aromatic nitrile linkers that also directed self-assembly into either spherical or worm-like micelles. In addition to the stabilization of organic colloids and integration of metal complexes, polypept(o)ides based on pSar-*b*-pGlu(ONa) have also been applied for the shielding of metal-organic frameworks (MOFs), metal-oxide surfaces [119,205,271].

With the purpose of making core cross-linked polypept(o)ide micelles biodegradable and responsive to intracellular glutathione (GSH) levels, Huesmann et al. introduced reactive *S*-alkylsulfonyl protecting groups for thiol-containing amino acids such as cysteine

and homocysteine [272–275]. The *S*-ethyl- and *S*-isopropylsulfonyl protective group combines stability towards amines (hard nucleophiles) and provides a high reactivity towards thiols (soft nucleophiles), which enables their use in NCA/NNCA polymerization followed by self-assembly in water and rapid bioreversible core-crosslinking by chemo-selective disulfide formation [196]. In combination with functional di- or olgio thiols containing cross-linkers, nanoparticle morphology and core- and surface functionality could be controlled in a single step [276]. Access to a wide range of payloads from hydrophobic drugs such as paclitaxel to hydrophilic small interfering RNAs (siRNAs) was thus created [196,276]. Of note, the secondary structure formation of the polypeptide segment governs the nanoparticle morphology and can be selected and tuned to define the desired shape [196,277].

The synthesis of multifunctional nanoparticles is commonly a complex endeavor that complicates the clinical translation of effective nanomedicines. To tackle this issue, Bauer et al. recently presented a microfluidic setup based on the aforementioned thiol-reactive pSar-*b*-pCys(SO2Et) polypept(o)ides and a combination of slit interdigital micromixers and tangential flow filtration [278]. The setup enabled the synthesis of core cross-linked polymeric micelles (CCPMs) in a continuous flow process that combined the commonly separated steps of micelle formation, core cross-linking, functionalization and purification into a single process. The precisely controlled microfluidic self-assembly process allowed the production of 350–700 mg of spherical CCPMs/h ($D_h = 35$ nm) with low polydispersity values (PDI<0.1) while the online tangential flow filtration removed impurities (unimer ≤ 0.5 %). In the given setup, the CCPMs displayed an ideal screening tool, as drug conjugation can be performed in an independent step. As a proof-of-concept, paclitaxel was conjugated to the micellar core via pH-sensitive hydrazone bonds. These paclitaxel-loaded CCPMs

showed the desired pH-responsive release profile, stable drug encapsulation and an improved toxicity profile compared to Abraxane, and therapeutic efficiency in the B16F1-xenotransplanted zebrafish model [278].

Just recently Bauer et al. transferred the concept of core cross-linked polymeric micelles (CCPMs) and presented these structures as basis for encapsulation of superparamagnetic iron oxide nanoparticles (SPIONs) and their potential for macrophage activation [279]. Colloidal SPION nanoparticles were encapsulated by co-self-assembly with pSar-*b*-pCys(SO$_2$Et) diblock polypept(o)ides and subsequently treated with dihydro lipoic acid, simultaneously stabilizing the PM by disulfide core cross-linking and the cargo by surface interaction of the carboxylic acid with the inorganic nanoparticle surface (Fig. 10A). Bioreversible cross-linking was nicely visualized by treatment with intracellular GSH levels (10 mM) causing the precipitation of iron oxide/phosphate, whereas minor effects were observed at extracellular reductive conditions (10 μM). Interestingly, treatment with SPION-loaded and non-loaded CCPMs on a co-culture of primary murine bone marrow-derived macrophages (BMDMs) and Lewis lung carcinoma cells (LLCs) resulted in a significantly higher accumulation of SPION-loaded micelles in BMDMs, whereas non-loaded micelles preferably ended up in LLCs. (Fig. 10B). On the cellular level, efficient iron delivery by CCPMs into BMDMs induced pro-inflammatory response by upregulating cytokines and characteristic surface proteins as summarized in Fig. 10C. Identical effects could be observed in human macrophages (Fig. 10D), pointing out the therapeutic potential of such systems. Finally, the effect was confirmed *in vivo*. Intratracheal administration of SPION-loaded micelles to wild-type C57Bl/6 N mice lead to elevated iron levels in lung macrophages and increased pro-inflammatory cytokines and surface markers (Fig. 10E). The immunomodulatory properties could even outperform commercial iron sources like Feraheme and display a promising approach as an adjuvant in cancer therapy, in particular, in combination with other medicines. Recently, Horvat et al. reported on the delayed tumor regrowth in lung cancer-bearing mice (Eml4-Alk) when the initial treatment with Crizotinib was followed by the intratracheal administration of SPION−CCPMs [280].

4.2. Polymersomes

Besides PMs as self-assembled structures from amphiphilic block copolymers, polymersomes, so-called Peptosomes, have been established from polymers with higher ratio of the hydrophobic segment by Tanisaka et al. using pSar-*b*-pGlu(OMe) [281]. By representing one of the first applicational approaches of polypept(o)ides, near-infrared fluorescent labeled peptosomes were used for cancer imaging in SUIT2/EF-luc xenograft tumor bearing-mice upon tail vein injection. Retention in the blood stream were comparable to PEGylated liposomes and pronounced accumulation was detected in tumor tissues [281]. Contrary to classical micellar constructs, Peptosomes further allow for encapsulation of hydrophobic and/or hydrophilic cargo due to their vesicular structure. Later, Weber et al. utilized pSar-*b*-pGlu(OBn) to prepare Peptosomes encapsulating the antigen (SIINFEKL) and the adjuvant (CpG) at the same time, aiming for a vaccination approach. The authors demonstrated the activation of BMDCs, characterized by enhanced expression of activation markers and cytokine excretion. Additionally, antigen specific T-cell proliferation was observed, indicating processing of the loaded antigen by BMDCs [282].

4.3. Non-Viral delivery systems for nucleic acids

Due to the remarkable success of mRNA vaccines against SARS-CoV-2 infections, lipid and polymer based delivery systems for nucleic acids have received widespread attention in pharmaceutical industry and research [157,283–285]. The strong anionic character of RNA or DNA requires cationic counterparts to form a complex by electrostatic interaction. Therefore, various lipid- or polymer-based delivery systems have been developed and tested, culminating in the final mRNA lipid vaccines BNT162b2 "Comirnaty" (BioNTech/Pfizer) and mRNA-1273 "Spikevax" (Moderna). While during the broad application of such vaccines initial concerns regarding the immunogenicity of PEGylated lipids have been raised, substitutes for PEG have been investigated and in particular pSar has shown an improved immunological profile [23,24,54,128].

Besides lipid-based structures, polymer-based non-viral delivery systems for nucleic acids have been developed utilizing polypept(o)ides [21,65,203,286]. In the first publication on polyplexes from 2014, Heller et al. reported on the synthesis and evaluation of pSar-*b*-pLys diblock structures to complex plasmid DNA (pDNA) into so-called PeptoPlexes. Transfection ability was demonstrated *in vitro* by dose-depended enhanced green fluorescent protein (eGFP) expression of HEK293T cells without toxic side-effects [65]. Further development of the polymeric architecture created triblock copolymers by insertion of a second pLys block with orthogonal protective moiety, namely TFA and Boc. Thus, sequential deprotection gave access to partial and selective functionalization of the complexing segment [286]. In this respect, the significance of the block ionomer microstructure on the formation and transfection efficiency was investigated based on random- or blockwise alteration of the cationic block with pH-responsive imidazole groups. Supported by simulation studies, block structures were most effective in protecting pDNA from degradation and lead to highest transfection efficiencies outperforming the randomly modified copolymers [203].

Following these sequentially deprotectable triblock structures, Heller et al. further reported on disulfide-mediated stabilization by cross-linking structures, introduced by succinimidyl 3-(2-pyridyldithio)propionate (SPDP), a conceptualized in the Kataoka group's research [203,287]. Introducing this functional group enabled bio-reversible cross-linking by multifunctional cross-linkers, *e.g.* virus derived endosomolytic peptides, containing two or more thiols for bioreversible covalent stabilization of polyplexes (Fig. 11).

A) A few examples of cross-linker structures are displayed in Fig. 11.

B) Dynamic light scattering (DLS) experiments in human blood plasma as model for an *in vivo* environment revealed prevention of aggregate formation upon applying the cross-linking step (Fig. 11).

C) whereas non-cross linked PeptoPlexes showed the same significant aggregation caused by interaction with plasma proteins like LNPs or lipoplexes. By building up a library of PeptoPlexes introducing different cross-linker molecules, triethylenetetramine dicysteine (cTETAc) was identified as candidate with the best balance of stability, transfection and toxicity and therefore applied for further application as pDNA vaccine formulation for dendritic cell induced T cell stimulation (Fig. 11).

D) After transfection of DC2.4 cells with ovalbumin (OVA)-encoding pDNA by the PeptoPlex approach, cells were co-cultured with OVA-responsive CD8$^+$ *T* cells to evaluate stimulation. While polypept(o)ide material itself did not induce any detectable immune response, OVA-pDNA transfected cells induced strong T cell proliferation, even after pre-incubation with native mouse serum to mimic *in vivo* conditions. Stability, non-toxicity, pDNA transfection efficiency, specific immune activation by the cargo and no influence after serum incubation display the PeptoPlexes' potential as pDNA vaccine approach [286].

Fig. 10. A) Illustration of the synthesis of SPION-loaded CCPMs by co-self-assembly and subsequent cross-linking. B) In co-cultures of LLCs and BMDMs, SPION−CCPMs show significantly higher uptake in BMDMs compared to LLCs. Inverse effect for CCPMs without iron, as analyzed by FACS 24 h after incubation. C) Illustrative summary of SPION−CCPM-induced inflammatory response of macrophages. D) *In vitro* upregulation of inflammatory surface marker and cytokine levels as measured by protein and mRNA expression in human macrophages (compared to non-treated condition or corrected to *Rpl19*, respectively; as mean from three independent experiments). E) *In vivo* evaluation, 4 and 24 h after intratracheal administration of SPION−CCPMs to C57Bl/6 mice (red), compared to PBS treatment (black); represented by increased cell-surface marker CD80 in alveolar macrophages (left) and mRNA expression of pro-inflammatory cytokines Il1β in lung tissue (right). Reprinted from Bauer et al. [279]., © 2021, with permission from Wiley-VCH GmbH.

Following a similar strategy, Capelôa et al. implemented siRNA as cargo, by encapsulation into Polyion Complex Micelles (PICMs) comprising pSar-*b*-pCys(SO₂Et)-*b*-pLys triblock copolymers. Thus, introduction of a cross-linkable block-structure from previously mentioned micellar approaches was combined with the complexing abilities of PeptoPlexes [67]. This approach avoids the post-polymerization modification used by Heller et al. and allows for the direct chemo-selective formation of asymmetric disulfides stabilizing the PeptoPlexes.

Stabilization of PICMs can be also achieved by non-covalent interactions, such as π-π interactions. Schneider and coworkers have utilized this strategy to combine a polycation namely pLys, with pGlu(OBn) and pSar [288]. These pSar-*b*-pGlu(OBn)-*b*-pLys enable the simultaneous encapsulation of siRNA and a cationic amphiphilic drug, desloratadine, by dual centrifugation. The cationic amphiphilic drug desloratadine help to overcome the limited endosomal escape properties of polyplexes, since upon protonation under acidic (endosomal) conditions the drug enables the endoso-

Fig. 11. A) Illustration of PeptoPlex formation by triblock copolypept(o)ides and pDNA with subsequent cross-linking step. B) Exemplary selection of evaluated disulfide cross-linker structures. C) DLS in human blood plasma of cross-linked PeptoPlexes. D) OT-I T cell proliferation upon co-cultering with transfected DC2.4 cells. DC2.4 cells were transfected with OVA encoding pDNA complexed by TETA-cross-linked PeptoPlexes or soluble OVA protein, either stimulated with immune activator LPS or left untreated prior to transfection. PeptoPlexes were partially incubated with native mouse serum 1:1 (v/v) (n = 3). Reprinted from Heller et al. [286]., © 2017, with permission from Elsevier Science Ltd.

mal escape of PICMs improving RNAi substantially. Therefore, therapeutic RNAi can be achieved in hepatocellular carcinoma in the liver, while Onpattro®-like LNPs fail to provide any therapeutic effect [282].

4.4. Molecular nanocarriers: Peptostars

Beyond self-assembled structures, also molecular nanocarriers have been prepared from polypept(o)ides [68,289]. Compared to their self-assembled counterparts, molecular nanocarriers are chemically synthesized and defined nanoparticles, whereby size and stability can be precisely controlled by chemical synthesis. In particular, carrier systems with small hydrodynamic diameters, high stability or defined architecture can easily be prepared by these techniques [2,182,290]. Since small NPs, just above the renal filtration limit (>10 nm), have shown superior passive or active tumor accumulation and penetration as explained above, star-like polymers seem to be ideal candidates for drug delivery to solid tumors, even though drug content per particle will be limited [242,291,292].

Fig. 12. A) General chemical structure of investigated 8-arm polypept(o)ide star architectures. B) Correlation of hydrodynamic radii of polymeric stars with increasing chain length of polysarcosine (S7 - S11) as evaluated by DLS in water at 5 g·L^{-1}. C) Passage of FITC-labeled S11 star-polymers through a polycarbonate membrane in the presence (circles) and absence (squares) of artificial mucus correlated to the time. D) P_{app} of FITC-labeled S11 at different concentrations and FD40 (2.5 g·L^{-1}) across isolated rat jejunal mucosae. Reprinted from Skoulas et al. [74]., © 2020, with permission from the American Chemical Society.

In 2017, Holm et al. introduced PeptoStars with Poisson-like molecular weight distribution and small hydrodynamic diameters [70,72,289,292]. Primarily, a library of 3-arm structured polymeric star architectures was presented. The core-first method was used starting from trifunctional initiators with or without GSH-responsive cleavable moieties. PSar-stars as well as core-shell structured 3-arm star architectures comprising a pLys core exhibited hydrodynamic diameters of 4 to 10 nm as determined by DLS and visualized by atomic force microscopy (AFM). Degradation studies cleaving off single arms by elevated GSH levels revealed homogenous and uniform arms, confirming a controlled synthetic approach [70]. In a follow-up study, riboflavin targeting moieties were utilized to enhance cellular internalization *in vitro* as well as *ex* and *in vivo*. Non-targeted and targeted 3-arm PeptoStars displayed an identical safety, circulation and biodistribution profile in balb/c tumor-bearing mice upon intravenous administration indicating successful shielding by the pSar corona. Moreover, riboflavin-conjugated structures presented higher cell-internalization within the tumor tissue demonstrating the effects of ligand-modification on passive and active tumor targeting [292]. Further, 6-arm star architectures based on pSar-*b*-pLys arms have been utilized as siRNA carrier system, presenting slightly increased hydrodynamic diameters of up to∼20 nm but still unimolecular appearance, even upon loading with siRNA [289]. However, the impact of branching revealed its importance when the peptidic core-material switched into hydrophobic, displayed by Holm et al. with pSar-*b*-pGlu(O*t*Bu) arm structures. Interestingly, supramolecular assembly in aqueous solution and human citrated plasma was observed for 3-arm but not for 6-arm structures. Further, fluorescence correlation spectroscopy (FCS) in human blood plasma revealed an effect on the shielding efficiency, since significant protein adsorption was observed for the 3-arm PeptoStars yet not for the 6-arm analogon [72]. Following research by Schwiertz et al. was focused on miktoarm star architectures, while consequences on the structure activity relationship for biomedical applications are the scope of current investigations [71].

Skoulas et al. investigated 8-arm core-shell star structures based on a poly(propyleneimine) dendrimer initiator and pSar-*b*-pGlu(OBn) arms (Fig. 12A). The tendency of aggregation could also be observed by high hydrodynamic diameters in DLS and shapes of elongated particles in TEM images, even for 8-arm PeptoStars. Most likely, this can be attributed to the strong hydrophobic character of pGlu(OBn) and additional aggregation driving forces like π-π-stacking and secondary structure formation. Nevertheless, increasing the sarcosine shell size by higher pSar chain lengths counteracted this effect, thus resulting in smaller particles (Fig. 12B). The authors evaluated the potential of this system to tackle the challenging task of overcoming mucus and epithelial barriers to enable non-invasive administration. As *ex vivo* model, FITC-labeled 8-arm PeptoStars presented the ability to penetrate through a polycarbonate membrane. An artificial mucus layer indeed lowered the speed but did not hinder membrane penetration (Fig. 12C). Finally, transepithelial permeability and thus therapeutic potential of this approach was evaluated by rat jejunal mucosa mounted in Franz diffusion cells and apical-side addition of the polypept(o)ide stars. The apparent permeability coefficient (P_{app}), displayed in Fig. 12D,

Fig. 13. A) Chemical and illustrative structure of TCO-modified PeptoBrushes synthesized by grafting-onto approach. B) Reaction kinetics for the Tz ligation of different PeptoBrushes with fluorogenic "turn-on" Tz 14 (HELIOS 347Me) and Tz 15 (HELIOS 388Me) compared to water-soluble TCO-derivative 16 ($n = 5$). "Corrected" data were related to single TCO-units. C) SPECT-image derived mean *in vivo* uptake values of [^{111}In]-modified PeptoBrush in tissues ($n = 4$) for evaluation of primary targeting abilities. D) Representative SPECT/CT images of pre-targeted imaging with PeptoBrush1 under optimized condition 2 h and 22 h p.i. *H*=heart, *L*=liver, *K*=Kidney, *B*=bladder, *T*=Tumor. Reprinted from Steen et al. [69]., © 2019, with permission from American Chemical Society.

revealed dose-dependent barrier crossing, comparable to FITC-labeled dextran (FD-40), but still almost a magnitude lower than positive controls like ketoprofen, a small molecule well-known for its high oral bioavailability. Histological investigations confirmed the material safety by the absence of tissue damage upon 2 h incubation. Overall, regardless of the underlying mechanism, the ability of penetrating and crossing mucus and epithelial barrier could be demonstrated [74]. Just recently, the researchers extended their 8-arm star-design by presenting core-shell star-polymers with pSar-pLys arms in both sequences as well as randomly structured. The authors demonstrated the ability of DNA-complexation by the polycationic structure as well as the ability of mucus penetration. Interestingly, the authors detected a strong structural dependency of the star-polymers on trypsin-mediated degradation. Increased levels of free lysine amino acid were detected after 48 h with a pLys outer layer in comparison to architectures with a pLys inner layer, demonstrating the shielding pSar-effect. The lowest levels, however, were detected at the randomly structured stars [293].

In the aim of increasing arm quantity of star-architectures, England et al. used lysine dendrimers as multifunctional initiators for sarcosine-NCA ROP [75]. With generation-five dendrimers 32-arm star polypept(o)ides were accessible. By increasing pSar chain lengths (28, 56 and 100) the hydrodynamic diameter grew from 10 nm to 18 nm, indicating unimolecular star polymers. Prolonged circulation half-lives of up to 88 h have been observed, correlating

with increased pSar chain length. Further, conjugation of the topoisomerase inhibitor SN-38 revealed great potential as anticancer treatment upon systemic injection of tumor-bearing mice (subcutaneous colorectal SW620 xenografted tumor model) by significant reduction of total tumor volume without loss of body weight. Further, Yu et al. just recently synthesized lysine based dendrimeric structures of different generations, to which a linear pSar was introduced yielding polypept(o)ide telodendrimers. Subsequent conjugation of the hydrophobic drug fulvestrant (Fulvestrant) generated amphiphilic polymers and enabled the formation of micelles with high drug loading and tunable size [76].

4.5. Molecular nanocarriers: Peptobrushes

Besides star-shaped polymers, research has also been conducted on the synthesis of cylindrical bottlebrush polypept(o)ides (PeptoBrushes). Here, grafting-onto as well as grafting-from strategies have been established.

Stéen et al. designed PeptoBrushes based on pGlu backbones with *trans*-cyclooctene (TCO) functionalization at the side chains (approx. 7.5 % to 30 %) and pSar polymers grafted onto residual pGlu functions (Fig. 13A) to enable pre-targeted imaging and therapy by *in vivo* click chemistry. More precisely, the *trans*-cyclooctene tetrazine (Tz) ligation *via* inverse electron demand Diels-Alder ligation was used [69]. The highest degree of TCO-functionalization

(PeptoBrush 1) encountered an enhancement of the reaction rate constants by two orders of magnitude compared to a simple water-soluble TCO derivative, as displayed in Fig. 13B. Supported by simulation studies as well as a positive correlation between lipophilicity of the Tz-derivative and the rate constant, the authors describe a specific function since the microphase separation of the TCO-modified amino acids undergo local clustering, which leads to an enhanced reactivity of TCOs by creating binding sides for lipophilic Tz-frameworks. Concurrently, the PeptoBrush demonstrated structural integrity in human plasma without appearance of aggregated products and further enabled an increased the TCO-moiety half-life, outlining pSar-mediated shielding and protection. For pre-targeted imaging and therapy, the TCO-PeptoBrush was administered first, whereby the small size ($\approx$ 10 nm) slightly above the value for renal filtration ensures optimal tumor tissue penetration [233,294]. When either tumor accumulation was highest (therapy) or blood levels were lowest (diagnosis), since non-accumulated PeptoBrushes were already excreted, a Tz-functionalized radiolabeled probe with a short circulation half-life was injected. Consequently, the radioactive probe is only retained at the location of the PeptoBrush after the successful ultra-fast click reaction between Tz and TCO. The seminal pre-targeting approach thus decoupled the tumor accumulation of the radiolabeled probe from the imaging step leading to enhanced contrast and reduced radiation exposure. The designed PeptoBrush was examined as excellent primary targeting agent, presenting passive tumor accumulation values of up to 5.1 $\pm$ 0.3%ID/g (22 h p.i.) upon intravenous injection of a [^{111}In]-labeled probe into CT26 tumor-bearing mice (mouse colorectal cancer), detected by single-photon emission computed tomography (SPECT) (Fig. 13C). Under optimized conditions for pre-targeted imaging the TCO-PeptoBrush enabled adequate image contrast of the tumor already 2 h after administration of the radiolabeled Tz (Fig. 13D). Particularly at early timepoints the pre-targeting strategy outperforms conventional imaging by resulting in higher image contrasts. Future developments will be directed to reduce the amount of residual PeptoBrush circulating in the blood by masking or clearing agents between the two steps to further increase the tumor-to-background ratio in imaging and directed effect of radionucleotide therapy.

Of note, the PeptoBrush-assisted TCO/Tz click reaction is among the fastest bio-orthogonal ligation techniques directing towards new drug release strategies (click-to-release) for tissue-selective drug release by functional nanomedicines. Interestingly polypept(o)ide-based micelles could not provide the unique combination of enhanced stability and higher TCO reactivity, but have been investigated with respect to microstructure variation by Johann et al. [295]. The authors utilized the TCO/Tz click reaction for a chemical ligation approach to form pSar-*b*-pGlu(OBn) from homopolymers synthesized with respective functional initiators. Moreover, the synthesis of an end-group Tz-functionalized diblock copolypept(o)ide enabled the formation of Tz-decorated PMs as well as organic colloids, displaying interesting candidates as masking or clearing agents in pre-targeted imaging or therapy strategies. Further, synthetic strategies have been developed for [^{11}C]-labeling of Tz-derivatives and thus the modified Pepto-Brushes. Thereby, PeptoBrush's *in vivo* fate upon injection was simplified to follow by the utility of positron emission tomography (PET) [69].

Besides the grafting-onto approach, which leads most of the time to spherical or slightly elongated polymer nanoparticles, the grafting-from approach has been realized first by Hörtz et al. in 2015 [68]. Here, cylindrical brush polymers were synthesized by utilizing PAHMA and pLys as backbones and multi-amine structures to initiate ROP of sarcosine-NNCA to generate the grafted pSar side chains. Moreover, the synthesis of core-shell brush-architectures has been described with PAHMA as backbone by

sequentially polymerizing Lys(TFA)-NCA and sarcosine-NNCA, and thus creating brushes with polypept(o)idic side chains. Upon TFA-deprotection, siRNA complexation was achieved by the polycationic core, enabling moderate knock-down efficiencies of ApoB100 mRNA in AML-12 hepatocytes in low-protein medium. However, reduced efficiency was observed in high-protein medium, correlating with reduced cellular uptake, likely caused by protein interaction of the secondary amine of pSar side chains.

This synthetic methodology was further improved and applied to pLys backbones with higher molecular weights with the vision to develop molecular vaccines based on cylindrical bottle brush polymers. The desired molecular vaccines shall enable the directed delivery of defined amounts of antigen and adjuvant to induce either antigen specific immunity or immune tolerance. Therefore, antibodies have been applied to provide specificity for specific immune cell types, *e.g.* dendritic cells or macrophages. On the way to develop such a molecular vaccine, Kappel et al. recently used PeptoBrushes based on a pLys backbone with a dense pSar corona generated by grafting-from approach (Fig. 14A) to demonstrate the significance of an average number of antibodies for active targeting of nanoparticles to dendritic cells *in vivo* [296,297]. Therefore, fluorescently labeled PeptoBrushes with grafted pSar$_{100}$ side chains were precisely engineered to bear on average either 2, 6, or 12 antibodies (anti-DEC205) per nanoparticle ($R_h \approx$ 23 nm), as pictured in Fig. 14B. Interestingly, circulation half-life evaluation revealed rapid uptake by liver sinusoidal endothelial cells and decreased circulation times were observed with increasing amounts of ligands per brush, which was attributed to the recognition by the Fc-receptor (Fig. 14C). Conversely, in biodistribution experiments, low amounts of anti-DEC205 were efficient for targeting the cells of the lymphoid organs bypassing liver accumulation, while high amounts of antiDEC205 forced accumulation in liver and spleen (Fig. 14D). Representing a platform to effectively and selectively accumulate in lymphoid organs, the research on these PeptoBrushes displays a suitable foundation for future development of systemic cancer vaccination strategies [296].

4.6. Applications beyond nanomedicine

Despite their major application as delivery platform in the field of nanomedicine, polypept(o)ides have already permeated into other applicational fields to deploy their potential as multifunctional material class. Considering the implication of pSar's stealth-mediating effect on surfaces in nanomedical approaches, most evident applicational extension is the control of macroscopic surface properties. Especially for biomedical devices, nonspecific protein adsorption, cell attachment and inflammatory reactions as biological responses as well as bacterial infections display major hurdles for their utility [298,299]. The design of antifouling and antibacterial surface coatings thus enables improved performances of these devices. Messersmith and co-workers therefore created pSar 10- and 20-mer coatings for TiO$_2$ surfaces utilizing a catechol-Lys pentapeptide anchor for surface attachment. PSar coatings effectively inhibited fibrinogen adsorption and resisted to attachment of mammalian or bacterial cells for several weeks [12]. Later, the authors utilized sequence-specific zwitterionic peptoid oligomer variants with similar surface attachment moieties to investigate their structure-property-relationship [300]. Starting from pGlu(O*t*Bu)-*b*-pSar diblock polymers, Yoo et al. highly increased the catechol amount per polymer by polymer-analogous functionalization of pGlu side chains [119]. Therefore, catechol moieties additionally could function as silver(I) ion reductant at the TiO$_2$ surface to induce the formation of interfacial silver nanoparticles as adjuvant antimicrobial agent.

For an almost contrary purpose, Yu and co-workers utilized polypept(o)ide-based hydrogels as tissue engineering scaffold plat-

Fig. 14. A) Chemical and B) illustrative structure of PeptoBrushes by grafting-from approach, decorated with variable amounts of aDEC205. On average 2, 6, and 12 antibodies were conjugated per PeptoBrush and analyzed for biodistribution and circulation time. C) Estimation of antibody-density-related liver uptake upon systemic injection of CW800-labeled PeptoBrushes by fluorescence intensities in blood at different timepoints ($n = 3$). D) Flow cytometric *ex vivo* quantification of systemically administered PeptoBrushes in liver, spleen, and lymph nodes (LN), 3 h and 24 h p.i. ($n = 6–8$, obtained from 2 to 3 experiments). Kappel et al. [296]., © 2021, reprinted with permission from the American Chemical Society.

form, enabling the internal cultivation of peripheral blood-derived mesenchymal stem cells (PBMSCs) as treatment for osteochondral defects [301]. The hydrogel comprised a mixture of an α-helical hyperbranched polypeptide p(2-(2-(2-methoxyethoxy) ethoxy)ethyl Glu-*co*-Cys) by copolymerization of respective NCAs, a four arm pSar with maleimide end-groups and the integrin-binding peptide CRGD (cysteine-arginine-glycine-aspartic acid). The authors demonstrated excellent promotion of PBMSC-mediated chondrogenesis within the hydrogel and subsequent promising osteochondral repair results in New Zealand white rabbits upon transplantation. Interestingly, pSar-based hydrogels outperformed PEG and methacryloyl gelatin analogues in this regard and further presented significantly reduced intra-articular immune response. Superior immunomodulatory performance was additionally confirmed by the least foreign body reaction and most macrophage polarization towards M2 phenotypes upon subcutaneous implantation into C57/BL6 mice.

5. Conclusions and outlook

During the last decade, polypept(o)ides have evolved as an auspicious class of materials entirely based on endogenous amino acids. Having provided a detailed overview on the origins and the state-of-the-art polypept(o)ide research for synthesis strategies, properties, and applications we conclude that this unique class of synthetic polymers combines high biocompatibility with

a high degree of architectural flexibility and chemical functionality. Polypept(o)ides can be derived by controlled living polymerization techniques providing convenient access to multiple polymer architectures. To date, most applications of polypept(o)ides, are related to nanomedicine, namely the delivery of small molecules and/or nucleic acids, molecular imaging approaches, and immune therapies. Complex tasks call for functional materials. Several key requirements in these areas can be already achieved by the combination of polypeptides and the polypeptoid pSar, including the translatability and certified production of polypept(o)ides. Therefore, the next years to come will provide further insight on the behavior of such materials in preclinical disease models and -in all probability- patients.

Besides exploring the biomedical use of polypept(o)ides and nanoparticulate systems thereof, multiple other research questions can be addressed. We consider the combination of polypeptoids with polypeptides particularly interesting, when one or both of these building blocks are obtained by modern methods for peptide synthesis, such as recombinant methods or a combination of solid phase chemistry and NCA/NNCA polymerization. Recently, the Weil lab has demonstrated the use of denatured human serum albumin (HSA) modified with ATRP initiators (2-bromoisobutanoic acid N-hydroxysuccinimide ester) can be used as defined backbone structure for the synthesis of uniform molecular polymer brushes with one distinctly addressable functionality [302]. This initial work demonstrates that natural proteins are suitable for a

use as macroinitiators in the synthesis of complex macromolecules and may serve as basis for polypept(o)ide nanoparticles with precise morphology and functionality.

Besides, the constant improvement of NCA polymerization methods addressing propagation rate and side reactions during the NCA ring opening polymerization [31,303] are increasingly applied to NNCA polymerizations. The use of carboxylic acids as catalysts for the ROP of sarcosine NCAs as reported by Lu and coworkers is a first example of improving control over the NNCA polymerization, which has also been applied to the polymerization of NCAs [124]. Catalytic processes like this will substantially accelerate the synthesis of polypept(o)ides and facilitate access to complex polymer architectures like multiblock copolymers. Especially in the area of nanomedicines we do expect a bright future for multiblock copolymers with tailored orthogonal reactivity segregated in individual blocks, which will allow the incorporation of defined functionalities in a single step, ideally under precisely controlled conditions. [278] In addition, the secondary structure directed self-assembly holds the potential to achieve non-spherical nanoparticles in a highly controlled fashion enabling an improved control over nanoparticles properties such as size, shape, and surface functionality.

In this respect, the recently reported synthesis of polypept(o)ide-based nanoparticles by polymerization induced self-assembly (PISA) will add additional flexibility [304]. So far the PISA process has been mainly demonstrated in aqueous solution [305], utilizing NCAs based on rather hydrophobic amino acids, to limit competing NCA hydrolysis. While this might be seen as a limitation, further exploration of PISA in other solvent combinations could facilitate the incorporation of more diverse NCAs with various functional groups and exploit the secondary structures of polypeptides to arrive at new and interesting nanostructures.

In addition to improvements in polypept(o)ide synthesis and functionality, we need to understand the long-term *in vivo* fate of these materials in relation to their envisioned administration routes, *e.g.*, intravenous-, sub cutaneous-, intramuscular- or intraperitoneal injection, transdermal, pulmonary, or oral administration. While polypept(o)ides are highly stability in water, early evidence suggests potential metabolic processing *in vivo*, highlighting that understanding the degradation pathways, kinetics, and end products will be essential next steps toward clinical translation. Hence, state-of-the-art analytical methods, such as advanced metabolomics, are to be applied in combination with different *in vitro* and *in vivo* models.

These efforts combined with the extensive macromolecular engineering possibilities, will cement our vision for polypept(o)ides as first-class polymer materials in drug and gene delivery.

In conclusion, we are convinced that polypept(o)ides will establish themselves as a class of polymers widely applied in nanomedicine, based on the extensive research efforts in both academia and industry compiled in this review, and the exciting developments in the years to come.

Declaration of competing interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

M.B. and T.A.B. are named as a co-inventor in the patent application Nanoparticles comprising iron oxide particles embedded in polymeric micelles, EP2021017. M.B. is named as a co-inventor in the following patents and patent applications Polypept(o)id-based Graft Copolymers for In Vivo Imaging by Tetrazine Transcyclooctene Click Chemistry, WO patent 2020002459A1 & Thiol-protected amino acid derivatives and uses thereof, WO patent 2,015,169,908. A. D. C. and V. J. N. are employes of Curapath (for-

mer PTS, Valencia, Spain). M. B. is member of the scientific advisory board of Curapath.

CRediT authorship contribution statement

Tobias Alexander Bauer: Writing – original draft, Visualization, Conceptualization. **Leon Simić:** Writing – original draft, Visualization. **Joachim F.R. Van Guyse:** Writing – review & editing, Writing – original draft, Conceptualization. **Aroa Duro-Castaño:** Writing – original draft, Visualization. **Vicent J. Nebot:** Writing – review & editing. **Matthias Barz:** Writing – review & editing, Writing – original draft, Visualization, Supervision, Project administration, Conceptualization.

Data availability

Data will be made available on request.

References

[1] Birke A, Huesmann D, Kelsch A, Weilbächer M, Xie J, Bros M, et al. Polypeptoid- block -polypeptide copolymers: synthesis, characterization, and application of amphiphilic block Copolypept(o)ides in drug formulations and miniemulsion techniques. Biomacromolecules 2014;15:548–57.

[2] Klinker K, Barz M. Polypept(o)ides: hybrid systems based on polypeptides and polypeptoids. Macromol Rapid Commun 2015;36:1943–57. doi:10.1002/marc.201500403.

[3] Birke A, Ling J, Barz M. Polysarcosine-containing copolymers: synthesis, characterization, self-assembly, and applications. Prog Polym Sci 2018;81:163–208. doi:10.1016/j.progpolymsci.2018.01.002.

[4] Simon RJ, Kania RS, Zuckermann RN, Huebner VD, Jewell DA, Banville S, et al. Peptoids: a modular approach to drug discovery. Proc Natl Acad Sci 1992;89:9367–71. doi:10.1073/pnas.89.20.9367.

[5] Zuckermann RN, Kerr JM, Kent SBH, Moos WH. Efficient method for the preparation of peptoids [oligo(N-substituted glycines)] by submonomer solid-phase synthesis. J Am Chem Soc 1992;114:10646–7. doi:10.1021/ja00052a076.

[6] Kirshenbaum K, Barron AE, Goldsmith RA, Armand P, Bradley EK, Truong KTV, et al. Sequence-specific polypeptoids: a diverse family of heteropolymers with stable secondary structure. Proc Natl Acad Sci U S A 1998;95:4303–8. doi:10.1073/pnas.95.8.4303.

[7] Secker C, Brosnan SM, Luxenhofer R, Schlaad H. Poly(α-Peptoid)s Revisited: synthesis, Properties, and Use as Biomaterial. Macromol Biosci 2015;15:881–91. doi:10.1002/mabi.201500023.

[8] Gangloff N, Ulbricht J, Lorson T, Schlaad H, Luxenhofer R. Peptoids and Polypeptoids at the Frontier of Supra- and Macromolecular Engineering. Chem Rev 2016;116:1753–802. doi:10.1021/acs.chemrev.5b00201.

[9] Sanborn TJ, Wu CW, Zuckermann RN, Barron AE. Extreme stability of helices formed by water-soluble poly-N-substituted glycines (polypeptoids) with α-chiral side chains. Biopolymers 2002;63:12–20. doi:10.1002/bip.1058.

[10] Mannige RV, Haxton TK, Proulx C, Robertson EJ, Battigelli A, Butterfoss GL, et al. Peptoid nanosheets exhibit a new secondary-structure motif. Nature 2015;526:415–20. doi:10.1038/nature15363.

[11] Weber B, Birke A, Fischer K, Schmidt M, Barz M. Solution Properties of Polysarcosine: from Absolute and Relative Molar Mass Determinations to Complement Activation. Macromolecules 2018;51:2653–61. doi:10.1021/acs.macromol.8b00258.

[12] Lau KHA, Ren C, Sileika TS, Park SH, Szleifer I, Messersmith PB. Surface-grafted polysarcosine as a peptoid antifouling polymer brush. Langmuir 2012;28:16099–107. doi:10.1021/la302131n.

[13] Astbury WT, Dalgliesh CE, Darmon SE, Sutherland GBBM. Studies of the Structure of Synthetic Polypeptides. Nature 1948;162:596–600. doi:10.1038/162596a0.

[14] Brosnan ME, Brosnan JT. The role of dietary creatine. Amino Acids 2016;48:1785–91. doi:10.1007/s00726-016-2188-1.

[15] Snow RJ, Murphy RM. Creatine and the creatine transporter: a review. Mol Cell Biochem 2001;224:169–81. doi:10.1023/A:1011908606819.

[16] Horner WH, Mackenzie CG. The biological formation of sarcosine. J Biol Chem 1950;187:15–22. doi:10.1016/S0021-9258(19)50923-1.

[17] Ogawa H, Gomi T, Takusagawa F, Fujioka M. Structure, function and physiological role of glycine N- methyltransferase. Int J Biochem Cell Biol 1998;30:13–26. doi:10.1016/S1357-2725(97)00105-2.

[18] Porter DH, Cook RJ, Wagner C. Enzymatic properties of dimethylglycine dehydrogenase and sarcosine dehydrogenase from rat liver. Arch Biochem Biophys 1985;243:396–407. doi:10.1016/0003-9861(85)90516-8.

[19] Glorieux FH, Scriver CR, Delvin E, Mohyuddin F. Transport and metabolism of sarcosine in hypersarcosinemic and normal phenotypes. J Clin Invest 1971;50:2313–22. doi:10.1172/JCI106729.

[20] Schneider M, Tang Z, Richter M, Marschelke C, Förster P, Wegener E, et al. Patterned Polypeptoid Brushes. Macromol Biosci 2016;16:75–81. doi:10.1002/mabi.201500314.

[21] Heller P, Birke A, Huesmann D, Weber B, Fischer K, Reske-Kunz A, et al. Introducing PeptoPlexes: polylysine-block-polysarcosine based polyplexes for transfection of HEK 293T cells. Macromol Biosci 2014;14:1380–95. doi:10.1002/mabi.201400166.

[22] Schneider M, Fetsch C, Amin I, Jordan R, Luxenhofer R. Polypeptoid Brushes by Surface-Initiated Polymerization of N-Substituted Glycine N - Carboxyanhydrides. Langmuir 2013;29:6983–8. doi:10.1021/la4009174.

[23] Weber B, Seidl L, Schwiertz D, Scherer M, Bleher S, Süss R, et al. Polysarcosine-Based Lipids: from Lipopolypeptoid Micelles to Stealth-Like Lipids in Langmuir Blodgett Monolayers. Polymers (Basel) 2016;8:427. doi:10.3390/polym8120427.

[24] Bleher S, Buck J, Muhl C, Sieber S, Barnert S, Witzigmann D, et al. Poly(Sarcosine) Surface Modification Imparts Stealth-Like Properties to Liposomes. Small 2019;15:1–10. doi:10.1002/smll.201904716.

[25] van den Berg AIS, CO Yun, Schiffelers RM, Hennink WE. Polymeric delivery systems for nucleic acid therapeutics: approaching the clinic. J Control Release 2021;331:121–41. doi:10.1016/j.jconrel.2021.01.014.

[26] Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov 2021;20:101–24. doi:10.1038/s41573-020-0090-8.

[27] Ong SY, Zhang C, Dong X, Yao SQ. Recent Advances in Polymeric Nanoparticles for Enhanced Fluorescence and Photoacoustic Imaging. Angew Chemie - Int Ed 2021;60:17797–809. doi:10.1002/anie.202101964.

[28] Haas H. PNI Tea Time Webinar Series: polysarcosine-Functionalized Lipid Nanoparticles for Therapeutic mRNA Delivery. 30062021 n.d.

[29] The Lubrizol Corporation. Apisolex Launch 2022.

[30] Challener CA. Excipients for Solubility Enhancement of Parenteral Formulations. Pharm Technol 2022;46:20–3.

[31] Rasines Mazo A, Allison-Logan S, Karimi F, Chan NJA, Qiu W, Duan W, et al. Ring opening polymerization of α-amino acids: advances in synthesis, architecture and applications of polypeptides and their hybrids. Chem Soc Rev 2020;49:4737–834. doi:10.1039/c9cs00738e.

[32] Song Z, Tan Z, Cheng J. Recent Advances and Future Perspectives of Synthetic Polypeptides from N-Carboxyanhydrides. Macromolecules 2019;52:8521–39. doi:10.1021/acs.macromol.9b01450.

[33] Huesmann D, Klinker K, Barz M. Orthogonally reactive amino acids and end groups in NCA polymerization. Polym Chem 2017;8:957–71. doi:10.1039/c6py01817c.

[34] Deming TJ. Synthesis of Side-Chain Modified Polypeptides. Chem Rev 2016;116:786–808. doi:10.1021/acs.chemrev.5b00292.

[35] Kricheldorf HR. Polypeptides and 100 years of chemistry of α-amino acid N-carboxyanhydrides. Angew Chemie - Int Ed 2006;45:5752–84. doi:10.1002/anie.200600693.

[36] Sun J, Zuckermann RN. Peptoid polymers: a highly designable bioinspired material. ACS Nano 2013;7:4715–32. doi:10.1021/nn4015714.

[37] Chan BA, Xuan S, Li A, Simpson JM, Sternhagen GL, Yu T, et al. Polypeptoid polymers: synthesis, characterization, and properties. Biopolymers 2018;109:1–25. doi:10.1002/bip.23070.

[38] Luxenhofer R, Fetsch C, Grossmann A. Polypeptoids: a perfect match for molecular definition and macromolecular engineering? J Polym Sci Part A Polym Chem 2013;51:2731–52. doi:10.1002/pola.26687.

[39] Heatley F, Bovey FA. Polymer nuclear magnetic resonance spectroscopy. XIV. The nuclear magnetic resonance spectrum of poly (isopropyl acrylate). Macromolecules 1968;1:303–4. doi:10.1021/ma60004a003.

[40] Edison JR, Spencer RK, Butterfoss GL, Hudson BC, Hochbaum AI, Paravastu AK, et al. Conformations of peptoids in nanosheets result from the interplay of backbone energetics and intermolecular interactions. Proc Natl Acad Sci USA 2018;115:5647–51. doi:10.1073/pnas.1800397115.

[41] Sisido M, Imanishi Y, Higashimura T. Monte Carlo Calculation on trans/cis/-Polysarcosine. Macromolecules 1976;9:389–95. doi:10.1021/ma60051a003.

[42] Ostuni E, Chapman RG, Holmlin RE, Takayama S, Whitesides GM. A survey of structure-property relationships of surfaces that resist the adsorption of protein. Langmuir 2001;17:5605–20. doi:10.1021/la010384m.

[43] Ostuni E, Chapman RG, Liang MN, Meluleni G, Pier G, Ingber DE, et al. Self-assembled monolayers that resist the adsorption of proteins and the adhesion of bacterial and mammalian cells. Langmuir 2001;17:6336–43. doi:10.1021/la010552a.

[44] Settanni G, Schäfer T, Muhl C, Barz M, Schmid F. Poly-sarcosine and Poly(Ethylene-Glycol) Interactions with Proteins Investigated Using Molecular Dynamics Simulations. Comput Struct Biotechnol J 2018;16:543–50. doi:10.1016/j.csbj.2018.10.012.

[45] Chen B-M, Cheng T-L, Roffler SR. Polyethylene Glycol Immunogenicity: theoretical, Clinical, and Practical Aspects of Anti-Polyethylene Glycol Antibodies. ACS Nano 2021;15:14022–48. doi:10.1021/acsnano.1c05922.

[46] Ju Y, Lee WS, Pilkington EH, Kelly HG, Li S, Selva KJ, et al. Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine. ACS Nano 2022;16:11769–80. doi:10.1021/acsnano.2c04543.

[47] Wheeler AW, Henderson DC, Garman AJ, Moran DM. Suppression of Murine IgE Responses with Amino Acid Polymer/Allergen Conjugates - II. Suppressive Activities in Adjuvant-Induced IgE Responses. Int Arch Allergy Immunol 1985;76:361–8. doi:10.1159/000233722.

[48] Cook RM, Henderson DC, Wheeler AW, Moran DM. Suppression of murine IgE responses with amino acid polymer/allergen conjugates - III. Activity *in vitro*. Int Arch Allergy Immunol 1986;80:355–60. doi:10.1159/000234081.

[49] Viricel W, Fournet G, Beaumel S, Perrial E, Papot S, Dumontet C, et al. Monodisperse polysarcosine-based highly-loaded antibody-drug conjugates. Chem Sci 2019;10:4048–53. doi:10.1039/C9SC00285E.

[50] Conilh L, Fournet G, Fourmaux E, Murcia A, Matera EL, Joseph B, et al. Exatecan antibody drug conjugates based on a hydrophilic polysarcosine drug-linker platform. Pharmaceuticals 2021;14:1–17. doi:10.3390/ph14030247.

[51] Hu Y, Hou Y, Wang H, Lu H. Polysarcosine as an Alternative to PEG for Therapeutic Protein Conjugation. Bioconjug Chem 2018;29:2232–8. doi:10.1021/acs.bioconjchem.8b00237.

[52] Son S, Ueda M, Taguchi K, Maruyama T, Takeoka S, Ito Y. Evasion of the accelerated blood clearance phenomenon by polysarcosine coating of liposomes. J Control Release 2020;322:209–16. doi:10.1016/j.jconrel.2020.03.022.

[53] Chen Y, Xu Z, Zhu D, Tao X, Gao Y, Zhu H, et al. Gold nanoparticles coated with polysarcosine brushes to enhance their colloidal stability and circulation time *in vivo*. J Colloid Interface Sci 2016;483:201–10. doi:10.1016/j.jcis.2016.08.038.

[54] Nogueira SS, Schlegel A, Maxeiner K, Weber B, Barz M, Schroer MA, et al. Polysarcosine-Functionalized Lipid Nanoparticles for Therapeutic mRNA Delivery. ACS Appl Nano Mater 2020;3:10634–45. doi:10.1021/acsanm.0c01834.

[55] Bi D, Unthan DM, Hu L, Bussmann J, Remaut K, Barz M, et al. Polysarcosine-based lipid formulations for intracranial delivery of mRNA. J Control Release 2023;356:1–13. doi:10.1016/j.jconrel.2023.02.021.

[56] Wilhelmy C, Keil IS, Uebbing L, Schroer MA, Franke D, Nawroth T, et al. Polysarcosine-Functionalized mRNA Lipid Nanoparticles Tailored for Immunotherapy. Pharmaceutics 2023;15:2068. doi:10.3390/pharmaceutics15082068.

[57] Vayaboury V, Giani O, Cottet H, Deratani A, Schué F. Living polymerization of α-amino acid N-carboxyanhydrides (NCA) upon decreasing the reaction temperature. Macromol Rapid Commun 2004;25:1221–4. doi:10.1002/marc.200400111.

[58] Aliferis T, Iatrou H, Hadjichristidis N. Living polypeptides. Biomacromolecules 2004;5:1653–6. doi:10.1021/bm0497217.

[59] Gangloff N, Fetsch C, Luxenhofer R. Polypeptoids by living ring-opening polymerization of N-substituted N-carboxyanhydrides from solid supports. Macromol Rapid Commun 2013;34:997–1001. doi:10.1002/marc.201300269.

[60] Bailey J. A new peptide synthesis. Nature 1949;164:889. doi:10.1038/164889a0.

[61] Merrifield RB. Solid phase peptide synthesis. I. The Synthesis of a Tetrapeptide. J Am Chem Soc 1963;85:2149–54. doi:10.1021/ja00897a025.

[62] Li Y. Recombinant production of antimicrobial peptides in Escherichia coli: a review. Protein Expr Purif 2011;80:260–7. doi:10.1016/j.pep.2011.08.001.

[63] Kawakami T, Murakami H, Suga H. Ribosomal Synthesis of Polypeptoids and Peptoid−Peptide Hybrids. J Am Chem Soc 2008;130:16861–3. doi:10.1021/ja806998v.

[64] Klinker K, Holm R, Heller P, Barz M. Evaluating chemical ligation techniques for the synthesis of block copolypeptides, polypeptoids and block copolypept(o)ides: a comparative study. Polym Chem 2015;6:4612–23. doi:10.1039/C5PY00461F.

[65] Heller P, Weber B, Birke A, Barz M. Synthesis and sequential deprotection of triblock Copolypept(o)ides using orthogonal protective group chemistry. Macromol Rapid Commun 2015;36:38–44. doi:10.1002/marc.201400466.

[66] Holm R, Klinker K, Weber B, Barz M. Synthesis of Amphiphilic Block Copolypept(o)ides by bifunctional initiators: making peptomicelles redox sensitive. Macromol Rapid Commun 2015;36:2083–91. doi:10.1002/marc.201500402.

[67] Capelôa L, Yazdi M, Zhang H, Chen X, Nie Y, Wagner E, et al. Cross-Linkable Polyion Complex Micelles from Polypept(o)ide-Based ABC-Triblock Copolymers for siRNA Delivery. Macromol Rapid Commun 2022;43:2100698. doi:10.1002/marc.202100698.

[68] Hörtz C, Birke A, Kaps L, Decker S, Wächtersbach E, Fischer K, et al. Cylindrical brush polymers with polysarcosine side chains: a novel biocompatible carrier for biomedical applications. Macromolecules 2015;48:2074–86. doi:10.1021/ma502497x.

[69] Stéen EJL, Jørgensen JT, Johann K, Nørregaard K, Sohr B, Svatunek D, et al. Trans-cyclooctene-functionalized peptobrushes with improved reaction kinetics of the tetrazine ligation for pretargeted nuclear imaging. ACS Nano 2020;14:568–84. doi:10.1021/acsnano.9b06905.

[70] Holm R, Weber B, Heller P, Klinker K, Westmeier D, Docter D, et al. Synthesis and Characterization of Stimuli-Responsive Star-Like Polypept(o)ides: introducing Biodegradable PeptoStars. Macromol Biosci 2017;17:1–14. doi:10.1002/mabi.201600514.

[71] Schwiertz D, Holm R, Barz M. Facile synthesis of amphiphilic AB3 and A3B miktoarm PeptoMiktoStars. Polym J 2020;52:119–32. doi:10.1038/s41428-019-0269-1.

[72] Holm R, Douverne M, Weber B, Bauer T, Best A, Ahlers P, et al. Impact of branching on the solution behavior and serum stability of star-

like block copolymers. Biomacromolecules 2019;20:375–88. doi:10.1021/acs.biomac.8b01545.

[73] Capelôa L, Schwiertz D, Barz M. Facile synthesis of AA'B- and ABC-type polypept(o)ide miktoarm star polymers utilizing polysarcosine end group functionalization for core introduction. Eur Polym J 2023;187. doi:10.1016/j.eurpolymj.2023.111896.

[74] Skoulas D, Stuettgen V, Gaul R, Cryan SA, Brayden DJ, Heise A. Amphiphilic Star Polypept(o)ides as Nanomeric Vectors in Mucosal Drug Delivery. Biomacromolecules 2020;21:2455–62. doi:10.1021/acs.biomac.0c00381.

[75] England RM, Moss JI, Gunnarsson A, Parker JS, Ashford MB. Synthesis and Characterization of Dendrimer-Based Polysarcosine Star Polymers: well-Defined, Versatile Platforms Designed for Drug-Delivery Applications. Biomacromolecules 2020;21:3332–41. doi:10.1021/acs.biomac.0c00768.

[76] Yu Q, England RM, Gunnarsson A, Luxenhofer R, Treacher K, Ashford MB. Designing Highly Stable Poly(sarcosine)-Based Telodendrimer Micelles with High Drug Content Exemplified with Fulvestrant. Macromolecules 2022;55:401–12. doi:10.1021/acs.macromol.1c02086.

[77] Katchalski E. Poly-α-Amino Acids. Adv Protein Chem 1951;6:123–85. doi:10.1016/S0065-3233(08)60503-3.

[78] Kricheldorf HR, Schilling G. 13C NMR sequence analysis, 15. Copolymerization of alanine-NCA with other α-amino acid NCAs. J Macromol Sci-Chem 1978;179:1175–91. doi:10.1002/macp.1978.021790506.

[79] Katchalski E, Sela M. Synthesis and chemical properties of poly-α-amino acids. Adv Protein Chem 1958;13:243–492. doi:10.1016/S0065-3233(08)60600-2.

[80] Katchalski E, Berger A, Bichowsky-Slomnicki L, Kurtz J. Antibiotically active amino-acid copolymers related to gramicidin S. Nature 1955;176:118–19. doi:10.1038/176118a0.

[81] Kidchob T, Kimura S, Imanishi Y. Preparation, structure and release profile of polypeptide microcapsules. J Control Release 1996;40:285–91. doi:10.1016/0168-3659(95)00196-4.

[82] Kidchob T, Kimura S, Imanishi Y. pH-responsive release from polypeptide microcapsules. J Appl Polym Sci 1997;63:453–8. doi:10.1002/(sici)1097-4628(19970124)63:4⟨453::aid-app6⟩3.0.co;2-q.

[83] Kidchob T. Thermoresponsive release from poly(Glu(OMe))-block-poly(Sar) microcapsules with surface-grafting of poly(N-isopropylacrylamide). J Control Release 1998;50:205–14. doi:10.1016/S0168-3659(97)00135-1.

[84] Kidchob T, Kimura S, Imanishi Y. Amphiphilic poly(Ala)-b-poly(Sar) microspheres loaded with hydrophobic drag. J Control Release 1998;51:241–8. doi:10.1016/S0168-3659(97)00176-4.

[85] Kimura S, Kidchob T, Imanishi Y. Controlled release from amphiphilic polymer aggregates. Polym Adv Technol 2001;12:85–95. doi:10.1002/1099-1581(200101/02)12:1/2⟨85::AID-PAT947⟩3.0.CO;2-8.

[86] Leuchs H. Ueber die Glycin-carbonsäure. Berichte Der Dtsch Chem Gesellschaft 1906;39:857–61. doi:10.1002/cber.190603901133.

[87] Leuchs H, Manasse W. Über die Isomerie der Carbäthoxyl-glycyl glycinester. Berichte Der Dtsch Chem Gesellschaft 1907;40:3235–49. doi:10.1002/cber.19070400387.

[88] Leuchs H, Geiger W. Über die Anhydride von α-Amino-N-carbonsäuren und die von α-Aminosäuren. Berichte Der Dtsch Chem Gesellschaft 1908;41:1721–6. doi:10.1002/cber.19080410232.

[89] Staudinger H. Über Polymerisation. Berichte Der Dtsch Chem Gesellschaft (A B Ser 1920;53:1073–85. doi:10.1002/cber.19200530627.

[90] Wessely F. Untersuchungen über α-Amino-N-Carbonsäureanhydride. I. Hoppe-Seylerś Zeitschrift Für. Physiol Chemie 1925;146:72–90. doi:10.1515/bchm2.1925.146.1-3.72.

[91] Go Y, Tani H. Über die hochkondensierten Produkte aus einigen Aminosäuren. Bull Chem Soc Jpn 1939;14:510–16.

[92] Sigmund F, Wessely F. Untersuchungen über α-Amino-N-Carbonsäureanhydride. II. Hoppe-Seylerś Zeitschrift Für Physiol Chemie 1926;157:91–105. doi:10.1515/bchm2.1926.157.1-3.91.

[93] Wessely F, Sigmund F. Untersuchungen über α-Amino-N-Caxbonsäureanhydride. III. (Zur Kenntnis höhermolekalarer Verbindungen). Hoppe-Seylerś Zeitschrift Für Physiol Chemie 1926;159:102–19. doi:10.1515/bchm2.1926.159.1-4.102.

[94] Meyer KH, Go Y. Sur le soufre filiforme et sa structure. Helv Chim Acta 1934;17:1081–93. doi:10.1002/hlca.193401701136.

[95] Woodward RB, Schramm CH. Synthesis of protein analogs. J Am Chem Soc 1947;69:1551–2. doi:10.1021/ja01198a526.

[96] Waley SG, Watson J. The kinetics of the polymerization of sarcosine carbonic anhydride. Proc R Soc London Ser A Math Phys Sci 1949;199:499–517. doi:10.1098/rspa.1949.0151.

[97] Fessler JH, Ogston AG. Studies of the sedimentation, diffusion and viscosity of some sarcosine polymers in aqueous solution. Trans Faraday Soc 1951;47:667. doi:10.1039/tf9514700667.

[98] Ballard DG, Bamford CH. Kinetics of the Formation of Polypeptides from N-Carboxy-α-amino-acid Anhydrides. Nature 1953;172:907–8. doi:10.1038/172907a0.

[99] Hanby WE, Waley SG, Watson J. Synthetic polypeptides. Part I. J Chem Soc 1950:3009–13. doi:10.1039/jr9500003009.

[100] Ballard DGH, Bamford CH. Studies in polymerization. X. 'The chain-effect. Proc R Soc London Ser A Math Phys Sci 1956;236:384–96. doi:10.1098/rspa.1956.0143.

[101] Fuchs F. Über N-Carbonsäure-anhydride. Chem Ber 1922;55B:2943.

[102] Farthing AC, Reynolds RJW. Anhydro-N-Carboxy-DL-β-Phenylalanine. Nature 1950;165:647. doi:10.1038/165647a0.

[103] Oya M, Katakai R, Nakai H, Iwakura Y. A novel synthesis of N-Carboxy-α-Amino Acid Anhydride. Chem Lett 1973;2:1143–4. doi:10.1246/cl.1973.1143.

[104] Daly WH, Poché D. The preparation of N-carboxyanhydrides of α-amino acids using bis(trichloromethyl)carbonate. Tetrahedron Lett 1988;29:5859–62. doi:10.1016/S0040-4039(00)82209-1.

[105] Schäfer O, Schollmeyer D, Birke A, Holm R, Johann K, Muhl C, et al. Investigation of α-amino acid N-carboxyanhydrides by X-ray diffraction for controlled ring-opening polymerization. Tetrahedron Lett 2019;60:272–5. doi:10.1016/j.tetlet.2018.12.028.

[106] Laconde G, Amblard M, Martinez J. Synthesis of α-Amino Acid N-Carboxyanhydrides. Org Lett 2021;23:6412–16. doi:10.1021/acs.orglett.1c02224.

[107] Sugimoto T, Kuwahara T, Liang F, Wang H, Tsuda A. Photo-On-Demand Synthesis of α-Amino Acid N -Carboxyanhydrides with Chloroform. ACS Omega 2022;7:39250–7. doi:10.1021/acsomega.2c05299.

[108] Fischer K. Neues Verfahren zur maßanalytischen Bestimmung des Wassergehaltes von Flüssigkeiten und festen Körpern. Angew Chemie 1935;48:394–6. doi:10.1002/ange.19350482605.

[109] Semple JE, Sullivan B, Sill KN. Large-scale synthesis of α-amino acid- N -carboxyanhydrides. Synth Commun 2017;47:53–61. doi:10.1080/00397911.2016.1249289.

[110] Tian Z-Y, Zhang Z, Wang S, Lu H. A moisture-tolerant route to unprotected α/β-amino acid N-carboxyanhydrides and facile synthesis of hyperbranched polypeptides. Nat Commun 2021;12:5810. doi:10.1038/s41467-021-25689-y.

[111] Hadjichristidis N, Iatrou H, Pitsikalis M, Sakellariou G. Synthesis of Well-Defined Polypeptide-Based Materials via the Ring-Opening Polymerization of α-Amino Acid N -Carboxyanhydrides. Chem Rev 2009;109:5528–78. doi:10.1021/cr900044t.

[112] Webster OW. Living Polymerization Methods. Science (80-) 1991;251:887–93. doi:10.1126/science.251.4996.887.

[113] Deming TJ. Facile synthesis of block copolypeptides of defined architecture. Nature 1997;390:386–9. doi:10.1038/37084.

[114] Deming TJ. Cobalt and iron initiators for the controlled polymerization of α-amino acid-N-carboxyanhydrides. Macromolecules 1999;32:4500–2. doi:10.1021/ma9902899.

[115] Detwiler RE, Schlirf AE, Kramer JR. Rethinking Transition Metal Catalyzed N-Carboxyanhydride Polymerization: polymerization of Pro and AcOPro N-Carboxyanhydrides. J Am Chem Soc 2021;143:11482–9. doi:10.1021/jacs.1c03338.

[116] Conejos-Sánchez I, Duro-Castano A, Birke A, Barz M, Vicent MJ. A controlled and versatile NCA polymerization method for the synthesis of polypeptides. Polym Chem 2013;4:3182. doi:10.1039/c3py00347g.

[117] Dimitrov I, Schlaad H. Synthesis of nearly monodisperse polystyrene–polypeptide block copolymers via polymerisation of N-carboxyanhydrides. Chem Commun 2003:2944–5. doi:10.1039/B308990H.

[118] Habraken GJM, Peeters M, Dietz CHJT, Koning CE, Heise A. How controlled and versatile is N-carboxy anhydride (NCA) polymerization at 0 °C? Effect of temperature on homo-, block- and graft (co)polymerization. Polym Chem 2010;1:514–24. doi:10.1039/b9py00337a.

[119] Yoo J, Birke A, Kim J, Jang Y, Song SY, Ryu S, et al. Cooperative Catechol-Functionalized Polypept(o)ide Brushes and Ag Nanoparticles for Combination of Protein Resistance and Antimicrobial Activity on Metal Oxide Surfaces. Biomacromolecules 2018;19:1602–13. doi:10.1021/acs.biomac.8b00135.

[120] Bauer TA, Muhl C, Schollmeyer D, Barz M. Racemic S -(ethylsulfonyl)- dl -cysteine N -Carboxyanhydrides Improve Chain Lengths and Monomer Conversion for β-Sheet-Controlled Ring-Opening Polymerization. Macromol Rapid Commun 2021;42 2000470. doi:10.1002/marc.202000470.

[121] Ballard DGH, Bamford CH. Studies in polymerization - VII. The polymerization of N -carboxy-α-amino acid anhydrides. Proc R Soc London Ser A Math Phys Sci 1954;223:495–520. doi:10.1098/rspa.1954.0133.

[122] Siefker D, Williams AZ, Stanley GG, Zhang D. Organic acid promoted controlled ring-opening polymerization of α-amino acid-derived N-thiocarboxyanhydrides (NTAs) toward well-defined polypeptides. ACS Macro Lett 2018;7:1272–7. doi:10.1021/acsmacrolett.8b00743.

[123] Wang S, Lu H. Ring-opening polymerization of amino acid N -Carboxyanhydrides with unprotected/reactive side groups. I. d -penicillamine N -carboxyanhydride. ACS Macro Lett 2023;12:555–62. doi:10.1021/acsmacrolett.3c00065.

[124] Wang S, Lu M-Y, Wan S-K, Lyu C-Y, Tian Z-Y, Liu K, et al. Precision Synthesis of Polysarcosine via Controlled Ring-Opening Polymerization of N -Carboxyanhydride: fast Kinetics, Ultrahigh Molecular Weight, and Mechanistic Insights. J Am Chem Soc 2024;146:5678–92. doi:10.1021/jacs.3c14740.

[125] Zhao W, Lv Y, Li J, Feng Z, Ni Y, Hadjichristidis N. Fast and selective organocatalytic ring-opening polymerization by fluorinated alcohol without a cocatalyst. Nat Commun 2019;10:3590. doi:10.1038/s41467-019-11524-y.

[126] Xia Y, Song Z, Tan Z, Xue T, Wei S, Zhu L, et al. Accelerated polymerization of N-carboxyanhydrides catalyzed by crown ether. Nat Commun 2021;12. doi:10.1038/s41467-020-20724-w.

[127] Sun J., Ling J., Cen J., Miao Y. Amphiphilic polymer nanomicelle containing polydopamine amino acid-chelated ferric ions and application thereof. WO2019218960, 2019.

[128] Barz M., Weber B., Haas H., Heller P., Nogueira S., Schlegel A. RNA particles comprising polysarcosine. WO2020069718, 2018.

[129] Cryam S.-A., Heise A., Walsh D., O'Dwyer J., O'Brien F., Duffy G. Star polypeptides. WO2020128089, 2019.

[130] Moreno Manzano V., Giraldo Reboloso E., Requejo Aguilar R., Alastrue Agudo A., Vicent Docon M.J., Arminan De Benito A., et al. Polymeric conjugates and uses thereof. WO2020193802, 2020.

[131] Battaglia G., Castano A.D. Production of nanoparticles and microparticles. EP3962456, 2020.

[132] Haas H., Nogueira S., Schlegel A. Rna particles comprising polysarcosine. WO2021191265, 2021.

[133] Zhang H., Meng X. Preparation method and application of antibody drug conjugate. WO2022228493, 2022.

[134] Vicent Docon M.J., Castano A.D., Nebot V.J. Cross-linked star-shaped self-assembled polypeptides and its use as carriers in biomedical applications. WO2017025298, 2016.

[135] Herrera Munoz L., Dolz Pérez I., Felip Leon C., Nebot Carda V.J., Vicent Docón M.J. Star-Shaped pAsp-oligoamine derivatives. WO2023002012, 2023.

[136] Carles F.L., Dolz Perez I., Esteban Perez S., Herrera Munoz L., Nebot Carda V.J. Non-covalent shielding polymers. WO2023002014, 2023.

[137] Glodek M, Liebowitz S, McCarthy R, McNally G, Oksanen C, Schultz T, et al. Process robustness – A PQRI white paper. Pharm Eng 2006;26:1–11.

[138] Bertrand N, Leroux JC. The journey of a drug-carrier in the body: an anatomo-physiological perspective. J Control Release 2012;161:152–63. doi:10.1016/j.jconrel.2011.09.098.

[139] Duncan R. Polymer therapeutics: top 10 selling pharmaceuticals - What next? J Control Release 2014;190:371–80. doi:10.1016/j.jconrel.2014.05.001.

[140] Kircher MF. How can we apply the use of surface-enhanced Raman scattering nanoparticles in tumor imaging? Nanomedicine 2017;12:171–4. doi:10.2217/nnm-2016-0385.

[141] Barz M, Luxenhofer R, Schillmeier M. Quo vadis nanomedicine? Nanomedicine 2015;10:3089–91. doi:10.2217/nnm.15.156.

[142] Sindhwani S, Chan WCW. Nanotechnology for modern medicine: next step towards clinical translation. J Intern Med 2021;290:486–98. doi:10.1111/joim.13254.

[143] Arranja AG, Pathak V, Lammers T, Shi Y. Tumor-targeted nanomedicines for cancer theranostics. Pharmacol Res 2017;115:87–95. doi:10.1016/j.phrs.2016.11.014.

[144] Duncan R. Polymer therapeutics as nanomedicines: new perspectives. Curr Opin Biotechnol 2011;22:492–501. doi:10.1016/j.copbio.2011.05.507.

[145] Vert M, Doi Y, Hellwich K-H, Hess M, Hodge P, Kubisa P, et al. Terminology for biorelated polymers and applications (IUPAC Recommendations 2012). Pure Appl Chem 2012;84:377–410. doi:10.1351/PAC-REC-10-12-04.

[146] Bisso S, Leroux JC. Nanopharmaceuticals: a focus on their clinical translatability. Int J Pharm 2020;578. doi:10.1016/j.ijpharm.2020.119098.

[147] Soares S, Sousa J, Pais A, Vitorino C. Nanomedicine: principles, properties, and regulatory issues. Front Chem 2018;6:1–15. doi:10.3389/fchem.2018.00360.

[148] Lammers T, Ferrari M. The success of nanomedicine. Nano Today 2020;31:0–1. doi:10.1016/j.nantod.2020.100853.

[149] Ma WW, Hidalgo M. The winning formulation: the development of paclitaxel in pancreatic cancer. Clin Cancer Res 2013;19:5572–9. doi:10.1158/1078-0432.CCR-13-1356.

[150] Barenholz Y. Doxil® - The first FDA-approved nano-drug: lessons learned. J Control Release 2012;160:117–34. doi:10.1016/j.jconrel.2012.03.020.

[151] Markovsky E, Baabur-Cohen H, Eldar-Boock A, Omer L, Tiram G, Ferber S, et al. Administration, distribution, metabolism and elimination of polymer therapeutics. J Control Release 2012;161:446–60. doi:10.1016/j.jconrel.2011.12.021.

[152] Hashida M. Role of pharmacokinetic consideration for the development of drug delivery systems: a historical overview. Adv Drug Deliv Rev 2020;157:71–82. doi:10.1016/j.addr.2020.06.015.

[153] Mi P, Miyata K, Kataoka K, Cabral H. Clinical translation of self-assembled cancer nanomedicines. Adv Ther 2021;4:2000159. doi:10.1002/adtp.202000159.

[154] Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol 2015;33:941–51. doi:10.1038/nbt.3330.

[155] Quader S, Kataoka K. Nanomaterial-Enabled Cancer Therapy. Mol Ther 2017;25:1501–13. doi:10.1016/j.ymthe.2017.04.026.

[156] Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 2010;9:615–27. doi:10.1038/nrd2591.

[157] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:2603–15. doi:10.1056/nejmoa2034577.

[158] Schoenmaker L, Witzigmann D, Kulkarni JA, Verbeke R, Kersten G, Jiskoot W, et al. mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability. Int J Pharm 2021;601:120586. doi:10.1016/j.ijpharm.2021.120586.

[159] Delehedde C, Even L, Midoux P, Pichon C, Perche F. Intracellular routing and recognition of lipid-based mRNA nanoparticles. Pharmaceutics 2021;13:945. doi:10.3390/pharmaceutics13070945.

[160] Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2021;384:403–16. doi:10.1056/nejmoa2035389.

[161] Cabral H, Uchida S, Perche F, Pichon C. Nanomedicine-based approaches for mRNA delivery. Mol Pharm 2020;17:3654–84. doi:10.1021/acs.molpharmaceut.0c00618.

[162] Gómez-Aguado I, Rodríguez-Castejón J, Vicente-Pascual M, Rodríguez-Gascón A, Solinís MÁ, del Pozo-Rodríguez A. Nanomedicines to Deliver mRNA: state of the Art and Future Perspectives. Nanomater 2020;10:364 2020, Vol 10, Page 364. doi:10.3390/NANO10020364.

[163] Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat Rev Drug Discov 2021:0123456789. doi:10.1038/s41573-021-00283-5.

[164] Lammers T, Kiessling F, Hennink WE, Storm G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release 2012;161:175–87. doi:10.1016/j.jconrel.2011.09.063.

[165] Van Eerden RAG, Mathijssen RHJ, Koolen SLW. Recent clinical developments of nanomediated drug delivery systems of taxanes for the treatment of cancer. Int J Nanomedicine 2020;15:8151–66. doi:10.2147/IJN.S272529.

[166] Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev 2001;47:113–31. doi:10.1016/S0169-409X(00)00124-1.

[167] Ho KS, Shoichet MS. Design considerations of polymeric nanoparticle micelles for chemotherapeutic delivery. Curr Opin Chem Eng 2013;2:53–9. doi:10.1016/j.coche.2013.01.003.

[168] Anchordoquy TJ, Barenholz Y, Boraschi D, Chorny M, Decuzzi P, Dobrovolskaia MA, et al. Mechanisms and Barriers in Cancer Nanomedicine: addressing Challenges, Looking for Solutions. ACS Nano 2017;11:12–18. doi:10.1021/acsnano.6b08244.

[169] Ma P, Mumper RJ. Paclitaxel Nano-Delivery Systems: a Comprehensive Review. J Nanomed Nanotechnol 2013;4:1000164. doi:10.4172/2157-7439.1000164.

[170] Montero A, Fossella F, Hortobagyi G, Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 2005;6:229–39. doi:10.1016/S1470-2045(05)70094-2.

[171] Gelderblom H, Verweij J, Nooter K, Sparreboom A, Cremophor EL. Eur J Cancer 2001;37:1590–8. doi:10.1016/S0959-8049(01)00171-X.

[172] Sparreboom A, Van Teilingen O, Nooijen WJ, Beijnen JH. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle cremophor EL. Cancer Res 1996;56:2112–15.

[173] Gonzalez-Valdivieso J, Girotti A, Schneider J, Arias FJ. Advanced nanomedicine and cancer: challenges and opportunities in clinical translation. Int J Pharm 2021;599:120438. doi:10.1016/j.ijpharm.2021.120438.

[174] Talelli M, Rijcken CJF, Hennink WE, Lammers T. Polymeric micelles for cancer therapy: 3 C's to enhance efficacy. Curr Opin Solid State Mater Sci 2012;16:302–9. doi:10.1016/j.cossms.2012.10.003.

[175] Luxenhofer R. A tutorial translation of the description of the historically first polymer drug conjugate and its *in vivo* evaluation. Zeitschrift Fur Naturforsch - Sect C J Biosci 2020;75:303–11. doi:10.1515/znc-2020-0077.

[176] Jatzkewitz H. An ein kolloidales Blutplasma-Ersatzmittel (Polyvinylpyrrolidon) gebundenes Peptamin (Glycyl-ʟ-leucyl-mezcalin) als neuartige Depotform für biologisch aktive primäre Amine (Mezcalin). Zeitschrift Fur Naturforsch - Sect B. J Chem Sci 1955;10:27–31. doi:10.1515/znb-1955-0106.

[177] Jatzkewitz H. Über den Einbau physiologisch wirksamer Substanzen in ein kollodiales Blutplasma-Ersatzmittel. Hoppe Seyler's Zeitschrift Für Physiol Chemie 1954;297:149–56.

[178] Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003;2:347–60. doi:10.1038/nrd1088.

[179] Ringsdorf H. Structure and Properties of Pharmacologically Active Polymers. J Polym Sci Polym Symp 1975;153:135–53. doi:10.1002/polc.5070510111.

[180] Talelli M, Barz M, Rijcken CJFF, Kiessling F, Hennink WE, Lammers T. Core-crosslinked polymeric micelles: principles, preparation, biomedical applications and clinical translation. Nano Today 2015;10:93–117. doi:10.1016/j.nantod.2015.01.005.

[181] Anselmo AC, Mitragotri S. Nanoparticles in the clinic: an update. Bioeng Transl Med 2019;4:1–16. doi:10.1002/btm2.10143.

[182] Müllner M. Molecular polymer brushes in nanomedicine. Macromol Chem Phys 2016;217:2209–22. doi:10.1002/macp.201600086.

[183] Johnson BK, Prud'homme RK. Mechanism for Rapid Self-Assembly of Block Copolymer Nanoparticles. Phys Rev Lett 2003;91:118302. doi:10.1103/PhysRevLett.91.118302.

[184] Mai Y, Eisenberg A. Self-assembly of block copolymers. Chem Soc Rev 2012;41:5969–85. doi:10.1039/c2cs35115c.

[185] Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 2013;65:36–48. doi:10.1016/j.addr.2012.09.037.

[186] Vonarbourg A, Passirani C, Saulnier P, Benoit JP. Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials 2006;27:4356–73. doi:10.1016/j.biomaterials.2006.03.039.

[187] Cabral H, Miyata K, Osada K, Kataoka K. Block Copolymer Micelles in Nanomedicine Applications. Chem Rev 2018;118:6844–92. doi:10.1021/acs.chemrev.8b00199.

[188] Davis FF. The origin of pegnology. Adv Drug Deliv Rev 2002;54:457–8. doi:10.1016/S0169-409X(02)00021-2.

[189] Graham ML. Pegaspargase: a review of clinical studies. Adv Drug Deliv Rev 2003;55:1293–302. doi:10.1016/S0169-409X(03)00110-8.

[190] Varela-Moreira A, Shi Y, Fens MHAM, Lammers T, Hennink WE, Schiffelers RM. Clinical application of polymeric micelles for the treatment of cancer. Mater Chem Front 2017;1:1485–501. doi:10.1039/C6QM00289G.

[191] Cabral H, Kataoka K. Progress of drug-loaded polymeric micelles into clinical studies. J Control Release 2014;190:465–76. doi:10.1016/j.jconrel.2014.06.042.

[192] Irvine DJ, Dane EL. Enhancing cancer immunotherapy with nanomedicine. Nat Rev Immunol 2020;20:321–34. doi:10.1038/s41577-019-0269-6.

[193] McLaughlin CK, Logie J, Shoichet MS. Core and corona modifications for the design of polymeric micelle drug-delivery systems. Isr J Chem 2013;53:670–9. doi:10.1002/ijch.201300085.

[194] Logie J, Ganesh AN, Aman AM, Al-awar RS, Shoichet MS. Preclinical evaluation of taxane-binding peptide-modified polymeric micelles loaded with docetaxel in an orthotopic breast cancer mouse model. Biomaterials 2017;123:39–47. doi:10.1016/j.biomaterials.2017.01.026.

[195] Ulrich S. Growing prospects of dynamic covalent chemistry in delivery applications. Acc Chem Res 2019;52:510–19. doi:10.1021/acs.accounts.8b00591.

[196] Klinker K, Schäfer O, Huesmann D, Bauer T, Capelôa L, Braun L, et al. Secondary-structure-driven self-assembly of reactive polypept(o)ides: controlling size, shape, and function of core cross-linked nanostructures. Angew Chemie Int Ed 2017;56:9608–13. doi:10.1002/anie.201702624.

[197] He Z, Wan X, Schulz A, Bludau H, Dobrovolskaia MA, Stern ST, et al. A high capacity polymeric micelle of paclitaxel: implication of high dose drug therapy to safety and *in vivo* anti-cancer activity. Biomaterials 2016;101:296–309. doi:10.1016/j.biomaterials.2016.06.002.

[198] Grüne M, Luxenhofer R, Iuga D, Brown SP, Pöppler AC. 14N-1H HMQC solid-state NMR as a powerful tool to study amorphous formulations-an exemplary study of paclitaxel loaded polymer micelles. J Mater Chem B 2020;8:6827–36. doi:10.1039/d0tb00614a.

[199] Bangham AD, Horne RW. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. J Mol Biol 1964;8 660-IN10. doi:10.1016/S0022-2836(64)80115-7.

[200] Discher DE, Eisenberg A. Polymer Vesicles. Science (80-) 2002;297:967–73. doi:10.1126/science.1074972.

[201] Discher DE, Ahmed F. Polymersomes. Annu Rev Biomed Eng 2006;8:323–41. doi:10.1146/annurev.bioeng.8.061505.095838.

[202] Bleul R, Thiermann R, Maskos M. Techniques to Control Polymersome Size. Macromolecules 2015;48:7396–409. doi:10.1021/acs.macromol.5b01500.

[203] Heller P, Zhou J, Weber B, Hobernik D, Bros M, Schmid F, et al. The influence of block ionomer microstructure on polyplex properties: can simulations help to understand differences in transfection efficiency? Small 2017;13:1603694. doi:10.1002/smll.201603694.

[204] Soenen SJ, Parak WJ, Rejman J, Manshian B. (Intra)cellular stability of inorganic nanoparticles: effects on cytotoxicity, particle functionality, and biomedical applications. Chem Rev 2015;115:2109–35. doi:10.1021/cr400714j.

[205] Zimpel A, Al Danaf N, Steinborn B, Kuhn J, Höhn M, Bauer T, et al. Coordinative binding of polymers to metal-organic framework nanoparticles for control of interactions at the biointerface. ACS Nano 2019;13. doi:10.1021/acsnano.8b06287.

[206] Cai W, Chu CC, Liu G, Wáng YXJ. Metal-Organic Framework-Based Nanomedicine Platforms for Drug Delivery and Molecular Imaging. Small 2015;11:4806–22. doi:10.1002/smll.201500802.

[207] He C, Liu D, Lin W. Nanomedicine applications of hybrid nanomaterials built from metal-ligand coordination bonds: nanoscale metal-organic frameworks and nanoscale coordination polymers. Chem Rev 2015;115:11079–108. doi:10.1021/acs.chemrev.5b00125.

[208] Behzadi S, Serpooshan V, Tao W, Hamaly MA, Alkawareek MY, Dreaden EC, et al. Cellular uptake of nanoparticles: journey inside the cell. Chem Soc Rev 2017;46:4218–44. doi:10.1039/c6cs00636a.

[209] de Lázaro I, Mooney DJ. Obstacles and opportunities in a forward vision for cancer nanomedicine. Nat Mater 2021;20:1469–79. doi:10.1038/s41563-021-01047-7.

[210] Anselmo AC, Mitragotri S. Nanoparticles in the clinic. Bioeng Transl Med 2016;1:10–29. doi:10.1002/btm2.10003.

[211] Ragelle H, Danhier F, Préat V, Langer R, Anderson DG. Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures. Expert Opin Drug Deliv 2017;14:851–64. doi:10.1080/17425247.2016.1244187.

[212] Duncan R, Gaspar R. Nanomedicine(s) under the microscope. Mol Pharm 2011;8:2101–41. doi:10.1021/mp200394t.

[213] Park JH, Lee HK. Delivery routes for COVID-19 vaccines. Vaccines (Basel) 2021;9. doi:10.3390/vaccines9050524.

[214] Ols S, Yang L, Thompson EA, Pushparaj P, Tran K, Liang F, et al. Route of Vaccine Administration Alters Antigen Trafficking but Not Innate or Adaptive Immunity. Cell Rep 2020;30 3964-3971.e7. doi:10.1016/j.celrep.2020.02.111.

[215] Zhang L, Wang W, Wang S. Effect of vaccine administration modality on immunogenicity and efficacy. Expert Rev Vaccines 2015;14:1509–23. doi:10.1586/14760584.2015.1081067.

[216] Youn YS, Bae YH. Perspectives on the past, present, and future of cancer nanomedicine. Adv Drug Deliv Rev 2018;130:3–11. doi:10.1016/j.addr.2018.05.008.

[217] Zhang P, Zhai Y, Cai Y, Zhao Y, Li Y. Nanomedicine-based immunotherapy for the treatment of cancer metastasis. Adv Mater 2019;31:1–18. doi:10.1002/adma.201904156.

[218] Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer 2017;17:20–37. doi:10.1038/nrc.2016.108.

[219] Richtering W, Alberg I, Zentel R. Nanoparticles in the Biological Context: surface Morphology and Protein Corona Formation. Small 2020;16:2002162. doi:10.1002/smll.202002162.

[220] Docter D, Distler U, Storck W, Kuharev J, Wünsch D, Hahlbrock A, et al. Quantitative profiling of the protein coronas that form around nanoparticles. Nat Protoc 2014;9:2030–44. doi:10.1038/nprot.2014.139.

[221] Alberg I, Kramer S, Leps C, Tenzer S, Zentel R. Effect of core-crosslinking on protein corona formation on polymeric micelles. Macromol Biosci 2021;21:2000414. doi:10.1002/mabi.202000414.

[222] Owen SC, Chan DPY, Shoichet MS. Polymeric micelle stability. Nano Today 2012;7:53–65. doi:10.1016/j.nantod.2012.01.002.

[223] Hume DA. The mononuclear phagocyte system. Curr Opin Immunol 2006;18:49–53. doi:10.1016/j.coi.2005.11.008.

[224] Tsoi KM, Macparland SA, Ma XZ, Spetzler VN, Echeverri J, Ouyang B, et al. Mechanism of hard-nanomaterial clearance by the liver. Nat Mater 2016;15:1212–21. doi:10.1038/nmat4718.

[225] Chan WCW. Nanomedicine 2.0. Acc Chem Res 2017;50:627–32. doi:10.1021/acs.accounts.6b00629.

[226] Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett 1990;268:235–7. doi:10.1016/0014-5793(90)81016-H.

[227] Logie J, Owen SC, McLaughlin CK, Shoichet MS. PEG-graft density controls polymeric nanoparticle micelle stability. Chem Mater 2014;26:2847–55. doi:10.1021/cm500448x.

[228] Carstens Myrra G, Rijcken CJF. Multifunctional pharmaceutical nanocarriers, 4. New York, NY: Springer New York; 2008. doi:10.1007/978-0-387-76554-9.

[229] Lasic DD, Martin FJ. Stealth liposomes. Boca Raton: CRC Press; 1995.

[230] Barz M, Luxenhofer R, Zentel R, Vicent MJ. Overcoming the PEG-addiction: well-defined alternatives to PEG, from structure-property relationships to better defined therapeutics. Polym Chem 2011;2:1900–18. doi:10.1039/c0py00406e.

[231] Kwon GS, Yokoyama M, Okano T, Sakurai Y, Kataoka K. Biodistribution of micelle-forming polymer-drug conjugates. Pharm Res 1993;10:970–4. doi:10.1023/a:1018998203127.

[232] Kwon G, Suwa S, Yokoyama M, Okano T, Sakurai Y, Kataoka K. Enhanced tumor accumulation and prolonged circulation times of micelle-forming poly (ethylene oxide-aspartate) block copolymer-adriamycin conjugates. J Control Release 1994;29:17–23. doi:10.1016/0168-3659(94)90176-X.

[233] Du B, Yu M, Zheng J. Transport and interactions of nanoparticles in the kidneys. Nat Rev Mater 2018;3:358–74. doi:10.1038/s41578-018-0038-3.

[234] Soo Choi H, Liu W, Misra P, Tanaka E, Zimmer JP, Itty Ipe B, et al. Renal clearance of quantum dots. Nat Biotechnol 2007;25:1165–70. doi:10.1038/nbt1340.

[235] Yamaoka T, Tabata Y, Ikada Y. Body distribution profile of polysaccharides after intravenous administration. Drug Deliv 1993;1:75–82. doi:10.3109/10717549300013345.

[236] Yamaoka T, Tabata Y, Ikada Y. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J Pharm Sci 1994;83:601–6. doi:10.1002/jps.2600830432.

[237] Reske-Nielsen E, Bojsen-Møller M, Vetner M, Hansen JC. Polyvinylpyrrolidone-storage disease. Acta Pathol Microbiol Scand Sect A Pathol 2009;84A:397–405. doi:10.1111/j.1699-0463.1976.tb00133.x.

[238] Maeda H. The 35th anniversary of the discovery of EPR effect: a new wave of nanomedicines for tumor-targeted drug delivery—personal remarks and future prospects. J Pers Med 2021;11:229. doi:10.3390/jpm11030229.

[239] Shi Y, van der Meel R, Chen X, Lammers T. The EPR effect and beyond: strategies to improve tumor targeting and cancer nanomedicine treatment efficacy. Theranostics 2020;10:7921–4. doi:10.7150/thno.49577.

[240] Maeda H, Matsumoto T, Konno T, Iwai K, Ueda M. Tailor-making of protein drugs by polymer conjugation for tumor targeting: a brief review on smancs. J Protein Chem 1984;3:181–93. doi:10.1007/BF01040499.

[241] Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986;46:6387–92.

[242] Cabral H, Matsumoto Y, Mizuno K, Chen Q, Murakami M, Kimura M, et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol 2011;6:815–23. doi:10.1038/nnano.2011.166.

[243] Mochida Y, Cabral H, Kataoka K. Polymeric micelles for targeted tumor therapy of platinum anticancer drugs. Expert Opin Drug Deliv 2017;14:1423–38. doi:10.1080/17425247.2017.1307338.

[244] Wilhelm S, Tavares AJ, Dai Q, Ohta S, Audet J, Dvorak HF, et al. Analysis of Nanoparticle Delivery to Tumours. Nat Rev Mater 2016;1.

[245] van der Meel R, Lammers T, Hennink WE. Cancer nanomedicines: oversold or underappreciated? Expert Opin Drug Deliv 2017;14:1–5. doi:10.1080/17425247.2017.1262346.

[246] Lammers T, Kiessling F, Ashford M, Hennink W, Crommelin D, Strom G. Cancer nanomedicine: is targeting our target? Nat Rev Mater 2016;1:1–2. doi:10.1038/natrevmats.2016.69.

[247] Der Meel R Van, E Sulheim, Shi Y, Kiessling F, Mulder WJM. Smart cancer nanomedicine. Nat Nanotechnol 2019;14:1007–17. doi:10.1038/s41565-019-0567-y.

[248] Nichols JW, Bae YH. EPR: evidence and fallacy. J Control Release 2014;190:451–64. doi:10.1016/j.jconrel.2014.03.057.

[249] Sun D, Zhou S, Gao W. What went wrong with anticancer nanomedicine design and how to make it right. ACS Nano 2020;14:12281–90. doi:10.1021/acsnano.9b09713.

[250] Hare JI, Lammers T, Ashford MB, Puri S, Storm G, Barry ST. Challenges and strategies in anti-cancer nanomedicine development: an industry perspective. Adv Drug Deliv Rev 2017;108:25–38. doi:10.1016/j.addr.2016.04.025.

[251] Lee H, Shields AF, Siegel BA, Miller KD, Krop I, Ma CX, et al. 64Cu-MM-302 positron emission tomography quantifies variability of enhanced permeability and retention of nanoparticles in relation to treatment response in patients with metastatic breast cancer. Clin Cancer Res 2017;23:4190–202. doi:10.1158/1078-0432.CCR-16-3193.

[252] Poon W, Kingston BR, Ouyang B, Ngo W, Chan WCW. A framework for designing delivery systems. Nat Nanotechnol 2020;15:819–29. doi:10.1038/s41565-020-0759-5.

[253] Sofias AM, Combes F, Koschmieder S, Storm G, Lammers T. A paradigm shift in cancer nanomedicine: from traditional tumor targeting to leveraging the immune system. Drug Discov Today 2021;00. doi:10.1016/j.drudis.2021.02.017.

[254] Matsumoto Y, Nichols JW, Toh K, Nomoto T, Cabral H, Miura Y, et al. Vascular bursts enhance permeability of tumour blood vessels and improve nanoparticle delivery. Nat Nanotechnol 2016;11:533–8. doi:10.1038/nnano.2015.342.

[255] Sindhwani S, Syed A.M., Ngai J., Kingston B.R., Maiorino L., Rothschild J., et al. The entry of nanoparticles into solid tumours. Nat Mater n.d. https://doi.org/10.1038/s41563-019-0566-2.

[256] Kingston BR, Lin ZP, Ouyang B, MacMillan P, Ngai J, Syed AM, et al. Specific endothelial cells govern nanoparticle entry into solid tumors. ACS Nano 2021;15:14080–94. doi:10.1021/acsnano.1c04510.

[257] Biancacci I, Sun Q, Möckel D, Gremse F, Rosenhain S, Kiessling F, et al. Optical imaging of the whole-body to cellular biodistribution of clinical-stage PEG-b-pHPMA-based core-crosslinked polymeric micelles. J Control Release 2020;328:805–16. doi:10.1016/j.jconrel.2020.09.046.

[258] Cheng Y, Song S, Wu P, Lyu B, Qin M, Sun Y, et al. Tumor Associated Macrophages and TAMs-Based Anti-Tumor Nanomedicines. Adv Healthc Mater 2021;10:1–21. doi:10.1002/adhm.202100590.

[259] Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 2017;14:399–416. doi:10.1038/nrclinonc.2016.217.

[260] Greco F, Vicent MJ. Combination therapy: opportunities and challenges for polymer–drug conjugates as anticancer nanomedicines. Adv Drug Deliv Rev 2009;61:1203–13. doi:10.1016/j.addr.2009.05.006.

[261] Schäfer O, Barz M. Of thiols and disulfides: methods for chemoselective formation of asymmetric disulfides in synthetic peptides and polymers. Chem - A Eur J 2018;24:12131–42. doi:10.1002/chem.201800681.

[262] Heller P, Mohr N, Birke A, Weber B, Reske-Kunz A, Bros M, et al. Directed interactions of block copolypept(o)ides with mannose-binding receptors: peptomicelles targeted to cells of the innate immune system. Macromol Biosci 2015;15:63–73. doi:10.1002/mabi.201400417.

[263] Lebleu C, Rodrigues L, Guigner JM, Brûlet A, Garanger E, Lecommandoux S. Self-Assembly of PEG-b-PTMC Copolymers: micelles and Polymersomes Size Control. Langmuir 2019;35:13364–74. doi:10.1021/acs.langmuir.9b02264.

[264] Seifert R, Lushington GH, Mou TC, Gille A, Sprang SR. Inhibitors of membranous adenylyl cyclases. Trends Pharmacol Sci 2012;33:64–78. doi:10.1016/j.tips.2011.10.006.

[265] Johann K, Bohn T, Shahneh F, Luther N, Birke A, Jaurich H, et al. Therapeutic melanoma inhibition by local micelle-mediated cyclic nucleotide repression. Nat Commun 2021;12:5981. doi:10.1038/s41467-021-26269-w.

[266] Dal NJK, Schäfer G, Thompson AM, Schmitt S, Redinger N, Alonso-Rodriguez N, et al. Π–Π interactions stabilize PeptoMicelle-based formulations of Pretomanid derivatives leading to promising therapy against tuberculosis in zebrafish and mouse models. J Control Release 2023;354:851–68. doi:10.1016/j.jconrel.2023.01.037.

[267] Nishiyama N, Okazaki S, Cabral H, Miyamoto M, Kato Y, Sugiyama Y, et al. Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. Cancer Res 2003;63:8977–83.

[268] Subbiah V, Grilley-Olson JE, Combest A, Sharma N, Tran RH, Bobe I, et al. Phase 1b/2 Trial of NC-6004 (Nanoparticle Cisplatin) plus gemcitabine in patients with advanced solid tumors. Clin Cancer Res 2017:1–10. doi:10.1158/1078-0432.CCR-17-1114.

[269] Siemer S, Bauer TA, Scholz P, Breder C, Fenaroli F, Harms G, et al. Targeting cancer chemotherapy resistance by precision medicine-driven nanoparticle-formulated cisplatin. ACS Nano 2021;15:18541–56. doi:10.1021/acsnano.1c08632.

[270] Bauer TA, Eckrich J, Wiesmann N, Kuczelinis F, Sun W, Zeng X, et al. Photocleavable core cross-linked polymeric micelles of polypept(o)ides and ruthenium(II) complexes. J Mater Chem B 2021;9:8211–23. doi:10.1039/D1TB01336J.

[271] Steinborn B, Hirschle P, Höhn M, Bauer T, Barz M, Wuttke S, et al. Core-Shell Functionalized Zirconium-Pemetrexed Coordination Nanoparticles as Carriers with a High Drug Content. Adv Ther 2019;2:1900120. doi:10.1002/adtp.201900120.

[272] Huesmann D, Schäfer O, Braun L, Klinker K, Reuter T, Barz M. Exploring new activating groups for reactive cysteine NCAs. Tetrahedron Lett 2016;57:1138–42. doi:10.1016/j.tetlet.2016.01.104.

[273] Schäfer O, Huesmann D, Barz M. Poly(S -ethylsulfonyl- l -cysteines) for chemoselective disulfide formation. Macromolecules 2016;49:8146–53. doi:10.1021/acs.macromol.6b02064.

[274] Schäfer O, Huesmann D, Muhl C, Barz M. Rethinking cysteine protective groups: s -Alkylsulfonyl- l -Cysteines for chemoselective disulfide formation. Chem - A Eur J 2016;22:18085–91. doi:10.1002/chem.201604391.

[275] Muhl C, Schäfer O, Bauer T, Räder H-J, Barz M. Poly(S -ethylsulfonyl-l -homocysteine): an α-helical polypeptide for chemoselective disulfide formation. Macromolecules 2018;51:8188–96. doi:10.1021/acs.macromol.8b01442.

[276] Schäfer O, Klinker K, Braun L, Huesmann D, Schultze J, Koynov K, et al. Combining orthogonal reactive groups in block copolymers for functional nanoparticle synthesis in a single step. ACS Macro Lett 2017;6:1140–5. doi:10.1021/acsmacrolett.7b00678.

[277] Bauer TA, Imschweiler J, Muhl C, Weber B, Barz M. Secondary structure-driven self-assembly of thiol-reactive Polypept(o)ides. Biomacromolecules 2021;22:2171–80. doi:10.1021/acs.biomac.1c00253.

[278] Bauer TA, Schramm J, Fenaroli F, Siemer S, Seidl CI, Rosenauer C, et al. Complex structures made simple – continuous flow production of core cross-linked polymeric micelles for paclitaxel pro-drug-delivery. Adv Mater 2023;35:2210704. doi:10.1002/adma.202210704.

[279] Bauer TA, Horvat NK, Marques O, Chocarro S, Mertens C, Colucci S, et al. Core cross-linked polymeric micelles for specific iron delivery: inducing sterile inflammation in macrophages. Adv Healthc Mater 2021;10:2100385. doi:10.1002/adhm.202100385.

[280] Horvat NK, Chocarro S, Marques O, Bauer TA, Qiu R, Diaz-Jimenez A, et al. Superparamagnetic iron oxide nanoparticles reprogram the tumor microenvironment and reduce lung cancer regrowth after Crizotinib treatment. ACS Nano 2024;18:11025–41. doi:10.1021/acsnano.3c08335.

[281] Tanisaka H, Kizaka-Kondoh S, Makino A, Tanaka S, Hiraoka M, Kimura S. Near-infrared fluorescent labeled peptosome for application to cancer imaging. Bioconjug Chem 2008;19:109–17. doi:10.1021/bc7001665.

[282] Weber B, Kappel C, Scherer M, Helm M, Bros M, Grabbe S, et al. PeptoSomes for Vaccination: combining Antigen and Adjuvant in Polypept(o)ide-Based Polymersomes. Macromol Biosci 2017;17:1–6. doi:10.1002/mabi.201700061.

[283] Sahin U, Karikó K, Türeci Ö. MRNA-based therapeutics-developing a new class of drugs. Nat Rev Drug Discov 2014;13:759–80. doi:10.1038/nrd4278.

[284] Barbier AJ, Jiang AY, Zhang P, Wooster R, Anderson DG. The clinical progress of mRNA vaccines and immunotherapies. Nat Biotechnol 2022;40:840–54. doi:10.1038/s41587-022-01294-2.

[285] Verbeke R, Lentacker I, De Smedt SC, Dewitte H. The dawn of mRNA vaccines: the COVID-19 case. J Control Release 2021;333:511–20. doi:10.1016/j.jconrel.2021.03.043.

[286] Heller P, Hobernik D, Lächelt U, Schinnerer M, Weber B, Schmidt M, et al. Combining reactive triblock copolymers with functional cross-linkers: a versatile pathway to disulfide stabilized-polyplex libraries and their application as pDNA vaccines. J Control Release 2017;258:146–60. doi:10.1016/j.jconrel.2017.05.012.

[287] Miyata K, Kakizawa Y, Nishiyama N, Harada A, Yamasaki Y, Koyama H, et al. Block catiomer polyplexes with regulated densities of charge and disulfide cross-linking directed to enhance gene expression. J Am Chem Soc 2004;126:2355–61. doi:10.1021/ja0379666.

[288] Schneider P, Zhang H, Simic L, Dai Z, Schrörs B, Akilli-Öztürk Ö, et al. Multicompartment polyion complex micelles based on triblock Polypept(o)ides mediate efficient siRNA delivery to cancer-associated fibroblasts for antistromal therapy of hepatocellular carcinoma. Adv Mater 2024;2404784:1–18. doi:10.1002/adma.202404784.

[289] Holm R, Schwiertz D, Weber B, Schultze J, Kuhn J, Koynov K, et al. Multifunctional cationic peptostars as sirna carrier: influence of architecture and histidine modification on knockdown potential. Macromol Biosci 2020;20:1–17. doi:10.1002/mabi.201900152.

[290] Ren JM, McKenzie TG, Fu Q, Wong EHH, Xu J, An Z, et al. Star Polymers. Chem Rev 2016;116:6743–836. doi:10.1021/acs.chemrev.6b00008.

[291] Kunjachan S, Pola R, Gremse F, Theek B, Ehling J, Moeckel D, et al. Passive versus active tumor targeting using RGD- and NGR-modified polymeric nanomedicines. Nano Lett 2014;14:972–81. doi:10.1021/nl404391r.

[292] Darguzyte M, Holm R, Baier J, Drude N, Schultze J, Koynov K, et al. Influence of riboflavin targeting on tumor accumulation and internalization of peptostar based drug delivery systems. Bioconjug Chem 2020;31:2691–6. doi:10.1021/acs.bioconjchem.0c00593.

[293] Skoulas D, Fattah S, Wang D, Cryan SA, Heise A. Systematic study of enzymatic degradation and plasmid DNA complexation of mucus penetrating star-shaped Lysine/Sarcosine Polypept(o)ides with different block arrangements. Macromol Biosci 2022;22:1–9. doi:10.1002/mabi.202200175.

[294] Longmire M, Choyke PL, Kobayashi H. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine 2008;3:703–17. doi:10.2217/17435889.3.5.703.

[295] Johann K, Svatunek D, Seidl C, Rizzelli S, Bauer TA, Braun L, et al. Tetrazine- and trans -cyclooctene-functionalised polypept(o)ides for fast bioorthogonal tetrazine ligation. Polym Chem 2020;11:4396–407. doi:10.1039/D0PY00375A.

[296] Kappel C, Seidl C, Medina-Montano C, Schinnerer M, Alberg I, Leps C, et al. Density of conjugated antibody determines the extent of fc receptor dependent capture of nanoparticles by liver sinusoidal endothelial cells. ACS Nano 2021;15:15191–209. doi:10.1021/acsnano.1c05713.

[297] Alkilany AM, Zhu L, Weller H, Mews A, Parak WJ, Barz M, et al. Ligand density on nanoparticles: a parameter with critical impact on nanomedicine. Adv Drug Deliv Rev 2019;143:22–36. doi:10.1016/j.addr.2019.05.010.

[298] Wilson CJ, Clegg RE, Leavesley DI, Pearcy MJ. Mediation of biomaterial-cell interactions by adsorbed proteins: a review. Tissue Eng 2005;11:1–18. doi:10.1089/ten.2005.11.1.

[299] Ribeiro M, Monteiro FJ, Ferraz MP. Infection of orthopedic implants with emphasis on bacterial adhesion process and techniques used in studying bacterial-material interactions. Biomatter 2012;2:176–94. doi:10.4161/biom.22905.

[300] Lau KHA, Sileika TS, Park SH, Sousa AML, Burch P, Szleifer I, et al. Molecular Design of Antifouling Polymer Brushes Using Sequence-Specific Peptoids. Adv Mater Interfaces 2015;2:1–10. doi:10.1002/admi.201400225.

[301] Yang M, Zhang ZC, Yuan FZ, Deng RH, Yan X, Mao FB, et al. An immunomodulatory polypeptide hydrogel for osteochondral defect repair. Bioact Mater 2023;19:678–89. doi:10.1016/j.bioactmat.2022.05.008.

[302] Chen C, Wunderlich K, Mukherji D, Koynov K, Heck AJ, Raabe M, et al. Precision anisotropic brush polymers by sequence controlled chemistry. J Am Chem Soc 2020;142:1332–40. doi:10.1021/jacs.9b10491.

[303] Wu Y, Chen K, Wang J, Chen M, Dai W, Liu R. Recent advances and future developments in the preparation of polypeptides via N-Carboxyanhydride (NCA) ring-opening polymerization. J Am Chem Soc 2024. doi:10.1021/jacs.4c05382.

[304] Morrell AH, Warren NJ, Thornton PD. The production of polysarcosine-containing nanoparticles by ring-opening polymerization-induced self-assembly. Macromol Rapid Commun 2024;45:2400103. doi:10.1002/MARC.202400103.

[305] Lecommandoux S, Grazon C, Salas-Ambrosio P, Ibarboure E, Buol A, Garanger E, et al. Aqueous ring-opening polymerization-induced self-assembly (ROPISA) of N-carboxyanhydrides. Angew Chem Int Ed Engl 2019. doi:10.1002/anie.201912028.